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ABSTRACT 
 
 Glaucoma is a neurodegenerative protein misfolding disorder classified by 
increases in IOP, damage to retinal ganglion cells (RGCs), optic nerve (ON) head 
damage, and progressive irreversible blindness. Primary open-angle glaucoma (POAG) 
is the most common form of glaucoma, constituting over 90% of clinical cases. POAG is 
observed in patients where normal outflow channels, mainly the trabecular meshwork 
(TM), are exposed at the angle formed by the iris and cornea. However, due to TM 
cellular dysfunction, aqueous outflow resistance is increased preventing normal 
circulation of aqueous humor. Recent studies have shown that in 2-4% of POAG cases, 
increased intracellular levels of a secreted glycoprotein, called myocilin, are present in 
the TM.  
Myocilin is a 504aa glycoprotein, with an unknown precise function. Recent 
studies have postulated the importance of myocilin in oligodendrocyte differentiation, 
axonal myelination, and early apoptosis of retinal cells in development, but exact 
function is still widely debated. However, it is important to note that pathology 
associated with myocilin is only seen during POAG. Also, only cells of the TM exhibit 
toxicity when overexpressing mutant myocilin. In the normal eye, myocilin is secreted 
from the ER of TM cells, however, mutations in the MYOC gene lead to an aggregation-
prone form of the protein, which is inefficiently processed and degraded from the ER, 
leading to build-up and associated toxicity. There are over 70 known MYOC mutations 
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associated with glaucoma, with over 90% occurring in the C-terminal OLF domain. 
Some of the more common, pathological mutations are: I477N, Y437H, P370L, W286R, 
N480K. All of these mutations have been observed in patients with glaucoma, and all 
lead to build-up and aggregation of the mutant protein within the ER of TM cells.  
Recently, work out of our lab has discovered an interaction between mutant 
forms of myocilin and the chaperone Grp94. Grp94 is the resident Hsp90 isoform of the 
ER. Grp94 is an important chaperone in ER quality control, aiding in the output of 
properly folded secretory and membrane-bound proteins. Besides protein folding, other 
roles of Grp94 in the ER include: calcium buffering, roles in ER quality control (including 
targeting misfolded proteins for ERAD), peptide binding, and roles in ER stress. 
Generally, terminally misfolded proteins in the ER are degraded through ERAD; the 
Grp94 mediated shuttling of misfolded proteins to the ER trans-membrane machinery 
for ubiquitination and subsequent translocation to the cytosol for proteasomal 
degradation. However, in the case of POAG, ERAD is inefficient in mutant myocilin 
degradation, causing protein accumulation within the ER.  
In this study, we demonstrate that specific Grp94 inhibition of interaction with 
mutant or misfolded myocilin leads to myocilin degradation and subsequent lowering of 
protein accumulation in the TM, thus reducing downfield pathology associated with 
POAG. Grp94 preserves mutant myocilin in the ER of TM cells leading to protein 
accumulation and aggregation precipitating TM cellular dysfunction. We showed in 
various in vitro cell assays that Grp94 inhibition leads to a reduction in intracellular 
protein levels, while alleviating TM cellular toxicity. Furthermore, in the Tg-MYOCY437H 
mouse model of POAG, we showed that topical ocular administration of a specific 
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Grp94 inhibitor alleviated glaucomatous pathologies, including elevated IOP, myocilin 
accumulation in the TM, reduced scotopic/photopic visual responses, and RGC health 
and viability. Finally, we have proven the importance of ER-stress pathway malfunction 
in the development of POAG pathology, while also discovering the involvement of the 
autophagy mechanism for myocilin degradation following Grp94 inhibition.  
Overall, this work proves that Grp94 is an important regulator of myocilin 
pathology during POAG. While there are no current therapeutics on the market that 
directly target the underlying POAG disease mechanism, specific Grp94 inhibition 
shows great promise and should be considered for human clinical trials. If successful, 
specific targeted Grp94 inhibition could be the first curative therapeutic options for 
patients suffering from myocilin-associated POAG.  
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Chapter One1: 
Determining the client-chaperone relationship between Myocilin and Grp94 
during Primary Open-Angle Glaucoma 
 
1.1 Abstract 
Endoplasmic Reticulum-Associated Degradation (ERAD) is the traditional method for 
clearing and degrading misfolded proteins in the ER. This process involves the 
ubiquitination and translocation of misfolded proteins through the ER lumen to the 
cytosol for proteasomal degradation. A network of ER-associated chaperone proteins 
aid in this translocation, and are responsible for recognition of terminally misfolded 
proteins. In this work, we investigated whether the glaucoma-associated protein, 
myocilin, was processed through ERAD. Myocilin is a secretory protein that is normally 
transported through the ER-Golgi network, however, inherited genetic mutations in the 
MYOC gene lead to a protein product that readily misfolds and accumulates in the ER 
of trabecular meshwork (TM) cells. This protein accumulation precipitates cellular 
dysfunction and toxicity, ultimately leading to ER stress induced TM cell death. Using 
siRNA knockdown, we discovered that glucose-regulated protein 94 (Grp94), the ER-
associated homolog of heat shock protein 90 (Hsp90), directly recognizes and 
associates with mutant forms of myocilin. This recognition prevents normal ERAD, and 
leads to intra-ER mutant myocilin protein accumulation. Additionally, through genetic  
 
 
1 Portions of this work were previously published (Suntharalingam A et al, 2012) and are used 
with the permission of the publisher 
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manipulation, or therapeutic intervention, inhibition of Grp94 association with mutant 
myocilin led to intracellular clearance by autophagy, a robust degradation pathway for 
aggregation-prone proteins. This work suggests that therapeutic interventions, 
preventing Grp94 association with mutant myocilin, could be a viable option for patients 
suffering from cases of myocilin-associated glaucoma.  
 
1.2 Introduction 
Primary open-angle glaucoma (POAG) is a hereditary form of glaucoma closely 
linked to accumulation of the secretory protein, myocilin. Over 10% of juvenile-onset 
open angle glaucoma (JOAG) and 5% of adult-onset open angle glaucoma are 
associated with myocilin accumulation [1, 2]. Interestingly, although myocilin is a 
ubiquitous protein, the only disease-associated pathology caused by the protein 
appears to be related to trabecular meshwork (TM) cell dysfunction during POAG [3]. 
The trabecular meshwork is a specialized tissue network in the anterior chamber of the 
eye responsible for regulating the outflow of aqueous humor. TM cell dysfunction leads 
to aqueous humor outflow dysregulation causing elevated intraocular pressure (IOP). 
IOP elevation is a major pathological hallmark of POAG, leading to retinal cell 
dysfunction and irreversible blindness [4].  
Recent studies have shown that mutations in the MYOC gene, encoding the 
myocilin protein, lead to a protein product that accumulates in the endoplasmic 
reticulum (ER) of TM cells [5-9]. Mutant myocilin accumulation in the ER of TM cells 
leads to ER-associated cellular stress causing TM tissue network dysfunction and the 
known glaucoma phenotypes [10]. Interestingly, individuals with missense MYOC 
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mutations preventing the translation of myocilin [11], as well as myocilin knock-out mice 
[12] do not develop glaucomatous pathologies, classifying POAG pathology as a toxic 
gain-of-function. To date, over 70 MYOC mutations have been documented to be 
associated with POAG pathology, with a majority occurring in the C-terminal 
olfactomedin domain [13]. Mutant myocilin products have also been shown to readily 
aggregate, through presence of detergent insoluble protein species, forming aggregate 
species containing amyloid fibrils [14, 15].  
Previous myocilin-associated glaucoma research has centered on the 
development of therapeutics to alleviate protein aggregate toxicity by promoting 
myocilin secretion [7, 16-18]. Unfortunately, it is still not understood why, unlike other 
ER-associated mutant proteins, myocilin is inefficiently cleared through ER-associated 
degradation (ERAD). In the normal cell environment, terminally misfolded intra-ER 
proteins are chaperoned to the ER lumen where they are ubiquitinated and translocated 
to the cell cytosol for proteasomal degradation [19]. However, this process seems to be 
inadequate for degrading mutant myocilin protein. In the ER, chaperone proteins are 
responsible for the recognition of misfolded proteins and determining terminally 
misfolded proteins fate. Main intra-ER chaperones include glucose-regulated protein 94 
(Grp94), the ER-associated heat shock protein 90 (Hsp90), and glucose-regulated 
protein 78 (Grp78), an ER-associated member of the heat shock protein 70 (Hsp70) 
family, also referred to as BiP. While exact intra-ER chaperone-client relationships are 
still incomplete, studies have shown that both Grp94 and Grp78 associate with mutant 
myocilin, although Grp94 seems to be more selective in its client determination [16, 20].  
Interestingly, the significance of these chaperone associations with mutant myocilin still 
4 
 
remain unknown. Therefore, a more concise understanding of mutant myocilin 
mechanics during ER accumulation could lead to viable treatment options to reduce 
mutant myocilin accumulation by utilizing the ER quality-control machinery.  
In this work, we set to determine the molecular relationship between myocilin and 
the intra-ER chaperone network, and show the importance of Grp94 in mutant myocilin 
accumulation and degradation. Mutations in the MYOC gene facilitate the interaction 
between mutant myocilin and Grp94, leading to inefficient protein clearance via ERAD, 
precipitating TM cellular dysfunction and glaucomatous pathology. By inhibiting the 
interaction between Grp94 and mutant myocilin, whether through genetic manipulation 
or pharmacological inhibition, mutant myocilin is effectively cleared and degraded 
through an autophagic mechanism. Inhibiting Grp94 association with myocilin could 
represent a viable therapeutic target for myocilin-associated glaucoma treatment.  
 
1.3 Grp94 interacts with mutant myocilin, preserving it in the ER. 
It is well documented that biologically, properly folded myocilin is a secreted 
protein [8, 21]. Alternatively, studies have shown that mutations in the myocilin gene 
lead to intracellular accumulation [22-24]. Therefore, in order to properly study myocilin 
mechanics, physiologically relevant cell models must be utilized. For this, our group 
developed and tested stably-transfected tetracycline-inducible cells, expressing WT and 
I477N mutant myocilin. If these cells were to represent normal bodily function, one 
would expect WT myocilin to be heavily secreted, while mutant myocilin to accumulate 
intracellularly. To validate these cell models, we performed western blot analysis of 
intracellular protein levels, and dot-blot analysis of secreted protein. We observed that 
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in cells stably overexpressing WT myocilin, all of the protein was secreted, with no 
myocilin observed intracellularly. Alternatively, in cells overexpressing mutant I477N 
myocilin, all of the protein was observed intracellularly, with none being secreted (Fig 
1.1A). Additionally, we performed immunofluorescent co-localization studies on our cells 
stably overexpressing mutant I477N myocilin, to determine if the intracellular myocilin 
was accumulating within the ER. To do this, we stained for myocilin and calnexin, an ER 
marker, and observed co-localization. We found that intracellular mutant myocilin co-
localized with calnexin, showing that mutant myocilin was accumulating within the ER 
(Fig 1.1B). Together, this data proved that our stably over-expressing myocilin cell 
models emulated physiological function, where WT myocilin was heavily secreted, while 
mutant myocilin accumulates in the ER.  
Next, using our cell model, we wanted to determine the effect, if any, the client-
chaperone relationship had on intracellular or secreted levels of myocilin. To do this, we 
performed a siRNA screen on known ER-associated chaperones (Fig 1.2E). We 
observed that in cells overexpressing WT myocilin, chaperone knockdown had no effect 
on intracellular levels (Fig 1.2C) or secreted levels (Fig 1.2D) of myocilin. However, in 
cells overexpressing the I477N mutant form of myocilin, Grp94 knockdown led to a 
significant reduction in intracellular levels of myocilin (Fig 1.2A), while have no effect on 
secreted levels (Fig 1.2B). This led us to the conclusion that Grp94 plays a significant 
role in mutant myocilin accumulation. To further confirm this observation, we performed 
immunofluorescent staining on cells overexpressing I477N mutant myocilin and 
transfected with either control or Grp94 siRNA. Myocilin staining showed a 63% 
reduction in intracellular mutant myocilin levels following Grp94 knockdown (Fig 1.2F). 
6 
 
This result, in concert with the previous siRNA screen results, further validates Grp94 as 
a major component in intracellular mutant myocilin accumulation, providing a 
specialized target for further research.  
Next, we wanted to further determine the client-chaperone relationship Grp94 
and myocilin share. For this, we first performed a cycloheximide chase experiment on 
cells overexpressing I477N mutant myocilin, in the presence or absence of Grp94, to 
determine myocilin half-life under the described conditions. We observed, in the 
presence of Grp94, mutant myocilin had a half-life of approximately 7.6 hours, whereas 
in the absence of Grp94, mutant myocilin had a half-life of 2.9 hours (Fig 1.3A). This 
showed the presence of Grp94 preserved mutant myocilin, leading to increased protein 
deposition. Furthermore, we looked at insoluble protein accumulation by performing 
western blots on cells overexpressing I477N mutant myocilin with Grp94 either 
overexpressed with cDNA or knocked down with siRNA. We observed when Grp94 was 
knocked down, there was a reduction of both soluble and insoluble forms of myocilin, 
whereas cells overexpressing Grp94 had elevated insoluble and soluble intracellular 
protein (Fig 1.3B&C). This further validated our conclusion that Grp94 is preserving 
mutant myocilin intracellularly, while also showing that Grp94 is promoting insoluble 
protein aggregation.  
Finally, we wanted to determine Grp94 association with myocilin. For this, we 
performed western blots on myocilin co-IP cell lysates overexpressing WT or I477N 
mutant myocilin and probing for Grp94. We observed that Grp94 only associated with 
cells overexpressing mutant I477N myocilin, while cells overexpressing WT myocilin 
showed no Grp94 association whatsoever (Fig 1.4). These data proved that Grp94 only 
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associates with the mutant form of myocilin, while not associating with or effecting WT 
myocilin. Taken together, these data show a strong association between the ER-
associate chaperone Grp94 and mutant forms of myocilin. The presence of Grp94 leads 
to mutant myocilin sequestration within the ER, leading to protein accumulation and 
aggregation. However, following Grp94 knockdown, mutant myocilin is able to be 
degraded, albeit through an unknown mechanism.  
 
1.4 Grp94 inhibition of interaction with mutant myocilin leads to intracellular 
clearance via an autophagic mechanism. 
After proving that Grp94 affects intracellular levels of mutant myocilin, and 
knockdown of Grp94 leads to mutant myocilin clearance, we wanted to determine the 
specific mechanism of mutant myocilin clearance following Grp94 knockdown. 
Traditionally, terminally misfolded proteins in the ER are degraded through an ubiquitin-
dependent proteasomal degradation pathway, known as ER-associated degradation 
(ERAD) [25, 26]. Therefore, we hypothesized that mutant myocilin would be degraded 
by ERAD following Grp94 knockdown. To test this hypothesis, we first looked at protein 
ubiquitination in myocilin co-IP lysates of cells overexpressing WT, P370L, or I477N 
mutant myocilin. We observed ubiquitin association with mutant forms of myocilin only 
(Fig 1.5A). This further validated our hypothesis that accumulated mutant myocilin in the 
ER is being targeted for ERAD. To definitively evaluate ERAD involvement we looked at 
the effects of proteasomal inhibition on mutant myocilin clearance. We treated cells 
overexpressing I477N mutant myocilin with epoxomicin, an inhibitor of proteasomal 
degradation, and transfected the cells with either control or Grp94 siRNA. If ERAD was 
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responsible for mutant myocilin degradation, we would expect epoxomicin treatment to 
inhibit intracellular protein clearance. However, we observed significant reductions in 
intracellular mutant myocilin protein levels following Grp94 knockdown and proteasomal 
inhibition (Fig 1.5B). This led us to believe that mutant myocilin is in fact being degraded 
through an alternative autophagic mechanism. To test the involvement of autophagy in 
mutant myocilin degradation following Grp94 knockdown, we performed western blot 
analysis on lysates from cells overexpressing I477N mutant myocilin, transfected with 
Grp94 siRNA in addition to either Beclin1 or Lamp2 siRNA. Beclin1 and Lamp2 are 
main components of the autophagic mechanism [27, 28], therefore, if autophagy was 
responsible for mutant myocilin degradation following Grp94 knockdown, we would 
expect the knockdown of these autophagic components to inhibit myocilin clearance. 
Interestingly, knockdown of both Beclin1 (Fig 1.5C) and Lamp2 (Fig 1.5D) directly 
inhibited mutant myocilin clearance following Grp94 knockdown. This led up to the 
conclusion that following Grp94 knockdown, mutant myocilin is degraded through the 
robust autophagic mechanism.  
Finally, after showing the effects Grp94 gene knockdown had on mutant myocilin 
intracellular accumulation, we wanted to determine if pharmacological inhibition of 
Grp94 interaction with mutant myocilin would produce similar results. To do this, we 
performed two dose response curves using known pan-HSP90 inhibitors, 17-AAG and 
Celastrol, on cells overexpressing I477N mutant myocilin. We observed that these 
inhibitors produced a dose dependent reduction in intracellular levels of mutant myocilin 
(Fig 1.6A&B). Additionally, treatment with a steady concentration of 17-AAG provided a 
time-dependent reduction of intracellular mutant myocilin (Fig 1.6C). Interestingly, 
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varying concentrations of 17-AAG had no effect on WT myocilin secretion (Fig 1.6D). 
Finally, in collaboration with Dr. Brian Blagg at Kansas University, we received a Grp94 
specific inhibitor, and tested its ability to reduce intracellular mutant myocilin in a 
concentration dependent manner. We observed, similar to the pan-HSP90 inhibitors, 
that the specific Grp94 inhibitor reduced intracellular mutant myocilin dose dependently 
(Fig 1.6E). Taken together, these data revealed that specific pharmacological inhibition 
of Grp94 interaction with mutant myocilin was sufficient to produce intracellular 
degradation, providing a scaffold for further research and drug development.  
 
1.5 Conclusions 
Grp94 recognition and association with mutant myocilin produces intracellular 
protein accumulation. Targeting Grp94 interaction with mutant myocilin has proven to be 
viable method of reducing accumulated intracellular pathological myocilin. However, as 
we are the first to discover this interaction, many unknowns remain about the complex 
Grp94-mutant myocilin interaction as it relates to cell biology and POAG pathology. 
Additionally, as Grp94 is a ubiquitous molecular chaperone, adverse effects of global 
Grp94 inhibition remain unclear. Our initial specific Grp94 inhibitor proved potent at 
reducing intracellular mutant myocilin in a dose dependent manner, however, off-target 
effects remain unknown. Determining the chaperone-client relationship between Grp94 
and other client proteins will help to perpetuate the production of more specific 
pharmacological inhibitors, while also determining whether tissue-specific delivery 
systems would be necessary. While no current research focuses on the Grp94-myocilin 
interaction as it relates to POAG, Grp94 has been previously studied in terms of various 
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cancer phenotypes. With a relatively short client list, Grp94 has promise as a valid 
therapeutic target for the treatment of myocilin-associated POAG. More studies on this 
chaperone-client relationship, as well as the development of more potent/ less toxic 
inhibitors, transitioning to physiologically relevant POAG cell models, effects on multiple 
mutant myocilin subtypes, and success in in vivo animal models will reveal the validity 
of Grp94 as a target for myocilin-associated POAG treatment.  
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Figure 1.1 Validation of inducible cell model. (A) Dot blot and Western blot analysis 
of tetracycline-inducible HEK cells (iHEK) stably overexpressing either WT or I477N 
mutant myocilin. (B) Co-localization immunofluorescent images of iHEK cells 
overexpressing I477N mutant myocilin.   
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Figure 1.2 siRNA-mediated knockdown of Grp94 regulates levels of I477N, but not 
wild type, myocilin. (A) Western blot analysis of siRNA mediated knockdown of known 
ER-associated molecular chaperones in iHEK cells overexpressing I477N mutant 
myocilin. (B) Dot blot analysis of siRNA mediated knockdown of known ER-associated 
molecular chaperones in iHEK cells overexpressing I477N mutant myocilin. (C) Western 
blot analysis of siRNA mediated knockdown of known ER-associated molecular 
chaperones in iHEK cells overexpressing WT myocilin. (D) Dot blot analysis of siRNA 
mediated knockdown of known ER-associated molecular chaperones in iHEK cells 
overexpressing WT myocilin. (E) Western blot analysis to prove proper gene 
knockdown of previously mentioned chaperone siRNAs. (F) Immunofluorescent images 
of iHEK cells expressing I477N mutant myocilin transfected with either control or Grp94 
siRNA.  
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Figure 1.3 Grp94 preserves mutant myocilin. (A) Western blot analysis of 
cycloheximide chase experiment to test half-life of I477N mutant myocilin protein 
following transfection with either control or Grp94 siRNA. (B) Western blot analysis of 
soluble and insoluble myocilin species following transfection of control or Grp94 siRNA. 
(C) Western blot analysis of soluble and insoluble myocilin species following 
transfection of empty vector or Grp94 cDNA. 
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Figure 1.4 Association of Grp94 with mutant but not wild type myocilin. Western 
blot and dot blot analysis of myocilin co-IP cell lysates and media observing Grp94 
association with WT or I477N mutant myocilin.  
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Figure 1.5 Grp94 triages mutant myocilin through ERAD, enabling autophagic 
degradation following Grp94 knockdown. (A) Myocilin co-IP of cell lysates looking at 
ubiquitin association to various forms of myocilin. (B) Western blot analysis of iHEK 
I477N cell lysates treated with increasing concentration of epoxomicin to inhibit 
proteasomal degradation. Cells are transfected with either control or Grp94 siRNA and 
probed for ubiquitin. (C) Western blot analysis of iHEK I477N cells co-transfected with 
Grp94 siRNA and Beclin siRNA to inhibit autophagic degradation. (D) Western blot 
analysis of iHEK I477N cells co-transfected with Grp94 siRNA and Lamp2 siRNA to 
inhibit autophagic degradation. 
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Figure 1.6 Inhibition of the HSP90 chaperone complex reduces levels of the 
disease-causing I477N myocilin. (A) Dose dependent reduction of I477N mutant 
myocilin following treatment with the pan-Hsp90 inhibitor, 17AAG. (B) Dose dependent 
reduction of I477N mutant myocilin following treatment with the pan-Hsp90 inhibitor, 
Celastrol. (C) Time dependent reduction of I477N mutant myocilin following single 
concentration treatment (7.5uM) with 17AAG. (D) Dot blot analysis showing no change 
in WT myocilin secretion following increasing dosages of 17AAG. (E) Dose dependent 
reduction of I477N mutant myocilin following treatment with a novel specific Grp94 
inhibitor.  
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Chapter Two1: 
Exploiting the interaction between Grp94 and aggregated myocilin to treat 
glaucoma 
 
2.1 Abstract: 
Gain-of-function mutations in the olfactomedin domain of the MYOC gene facilitate the 
toxic accumulation of amyloid-containing myocilin aggregates, hastening the onset of the 
prevalent ocular disorder primary open-angle glaucoma. Aggregation of wild-type 
myocilin has been reported in other glaucoma subtypes, suggesting broader relevance of 
misfolded myocilin across the disease spectrum, but the absence of myocilin does not 
cause disease. Thus, strategies aimed at eliminating myocilin could be therapeutically 
relevant for glaucoma. Here, a novel and selective Grp94 inhibitor reduced the levels of 
several mutant myocilin proteins as well as wild type myocilin when forced to misfold in 
cells. This inhibitor rescued mutant myocilin toxicity in primary human trabecular 
meshwork cells. Mechanistically, in vitro kinetics studies demonstrate that Grp94 
recognizes on-pathway aggregates of the myocilin olfactomedin domain (myoc-OLF), 
accelerates rates of aggregation, and co-precipitates with myoc-OLF. These results 
indicate that aberrant myocilin quaternary structure drives Grp94 recognition, rather than  
 
 
1This work was previously published (Stothert AR et al, 2014) and is used with the permission of 
the publisher 
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peptide motifs exposed by unfolded protein. Inhibition of Grp94 ameliorates the effects of 
Grp94-accelerated myoc-OLF aggregation, and Grp94 remains in solution. In cells, when 
wild type myocilin is driven to misfold and aggregate, it becomes a client of Grp94 and 
sensitive to Grp94 inhibition. Taken together, the interaction of Grp94 with myocilin 
aggregates can be manipulated by cellular environment and genetics; this process can 
be exploited with Grp94 inhibitors to promote the clearance of toxic forms of myocilin.  
 
2.2 Introduction:  
Primary open-angle glaucoma (POAG) is a degenerative eye disease 
characterized by retinal ganglion cell loss and optic nerve head damage. This is often 
preceded by increased intraocular pressure (IOP) due to impaired aqueous humor outflow 
through the anterior anatomical segment called the trabecular meshwork (TM), leading to 
irreversible vision loss [16, 29-31]. Mutations in the MYOC gene, which encodes the 
myocilin protein, cause ~5% of hereditary POAG in populations throughout the world, 
including approximately 100,000 people in the US [32, 33]. As a result, the pathogenic 
mechanisms of mutant myocilin and its corresponding native biological function(s) have 
been subjects of intensive investigation over the past decade [22, 34-36]. Myocilin, 
composed of an N-terminal coiled-coil and 31 kDa C-terminal olfactomedin domain 
(myoc-OLF), is generally believed to be a secreted protein [37]. The majority of the non-
synonymous MYOC gene lesions known to cause POAG are found within myoc-OLF [2, 
38], leading to intracellular sequestration and aggregation [5, 8, 9, 14]. These 
observations suggest a functional link between this domain and pathogenicity. The vast 
majority of work in the field indicates that mutations in myocilin do in fact cause a toxic 
gain-of-function for the protein [11, 39].  
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Our team has recently provided a molecular basis for this toxicity: mutations in the 
OLF domain of myocilin promote the toxic aggregation of the myocilin protein into amyloid 
aggregates [38, 40]. This non-native structure is known to be nearly impossible to 
disaggregate, likely explaining why, unlike other proteins, mutant myocilin cannot be 
efficiently cleared by endoplasmic reticulum-associated degradation (ERAD) and instead 
accumulates in the ER, leading to activation of ER stress pathways and TM cell death. 
Indeed, we recently showed that knocking down or inhibiting the ER chaperone Grp94 
facilitates the degradation of mutant myocilin in cells via autophagy. Grp94 preserves 
mutant myocilin in the ER by attempting to force it through the ERAD pathway that 
involves the valosin containing protein (VCP/p97) and the proteasome.  
Here, we have identified a potent and selective Grp94 inhibitor that lowers the 
levels of several mutant myocilin species. Grp94 inhibition reduces the toxicity of mutant 
myocilin in human primary TM cells.  The mechanism for Grp94 association with myocilin 
is through its recognition of myocilin aggregates, not the folded mutant protein as 
originally hypothesized. Based on this observation, we show that even wild type (WT) 
myocilin, if misfolded and aggregated, can become a Grp94 client, and therefore can be 
successfully degraded by inhibiting Grp94. Since ocular hypertension in glaucoma is 
thought to be a result of the overexpression of WT myocilin [41, 42], Grp94 inhibition could 
be more broadly applicable to glaucoma treatment than just for individuals with inherited 
POAG.   
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2.3 Materials and Methods: 
2.3.1 Cell Culture 
HEK 293T cells were grown and maintained in Dulbecco’s modified Eagle’s 
Medium supplemented with 10% FBS (Invitrogen), penicillin (100 units/mL), streptomycin 
(100 µg/mL) and 1% GlutaMAX (Invitrogen) at 37 °C under 5% CO2. 
Stably-transfected iHEK cells expressing myocilin were grown and maintained in 
Dulbecco’s Modified Eagle’s Medium supplemented with 10% FBS (Invitrogen), penicillin 
(100 units/mL), streptomycin (100 µg/mL) and 1% GlutaMAX (Invitrogen) at 37 °C under 
5% CO2. For cell selection, the cells were supplemented with hygromycin B (200 µg/mL) 
(InvivoGen) and G418 (100 µg/mL) (Gibco). To induce myocilin expression in these cells, 
they were treated with 5 µg/uL tetracycline 24 h prior to transfection, or 48 h prior to 
treatment. 
Human trabecular meshwork cells (ScienCell) were plated on poly-L-Lysine coated 
plates at a ratio of 1:10 poly-l-lysine to ddH2O. Cells were kept and maintained in 
Fibroblast Medium (Sciencell) supplemented with 2% fetal bovine serum (ScienCell cat. 
0010), 1% fibroblast growth supplement (ScienCell cat. 2352), and 1% 
penicillin/streptomycin solution (ScienCell cat. 0503). HTM cells were maintained at 37 
°C under 5% CO2. 
 
2.3.2 cDNA and siRNA Transfection 
All myocilin cDNA constructs were a generous gift from Dr. Vincent Raymond 
(Laval University Hospital (CHUL) Research Hospital). Grp94 (SI02663738) and control 
(1027281) siRNA was purchased from Qiagen (Valencia, CA) [43]. 
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Plasmid transfections were carried out in serum-free opti-mem (Invitrogen) 
medium. cDNA was mixed with Lipofectamine 2000 (Invitrogen) transfection reagent at a 
ratio of 1 µg cDNA: 2.5 µL Lipofectamine 2000. cDNA was left on the cells for 48 h before 
harvest. siRNA transfections were carried out in serum-free opti-mem (Invitrogen) 
medium. siRNA was mixed with siLentFect (BioRad) lipid reagent for RNAi transfection. 
Next, 40 nM of siRNA was added to cells, so that the siRNA to siLentFect ratio was 1 µL 
siRNA to 2 µL siLentFect. siRNA was kept on the cells for 24 h prior to cDNA transfection 
or drug treatment.  
 
2.3.3 Antibodies 
Myocilin monoclonal antibody was purchased from R&D Systems (Minneapolis, 
MN (MAB3446)). Grp94 (2104S), Grp78 (3177S), Hsp70 (4873S), Hsp27 (2402S), and 
DYKDDDK (Flag) (8146S) monoclonal antibodies were purchased from Cell Signaling 
Technologies. Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) antibody 
(H86504M) was purchased from Meridian Life Science (Saco, ME). Actin antibody was 
purchased from Sigma (A5316). Secondary antibodies were all HRP-linked and 
purchased from Southern Biotechnolofies (Birmingham, AL). All antibodies were added 
to blots in a 1:1000 dilution in 7% milk. 
 
2.3.4 Pharmacological Treatment 
Grp94 inhibitors were solubilized in DMSO (Sigma), and added to cells at varying 
concentrations. All drug treatments were carried out for 24 h prior to cell harvest, and 
DMSO never exceeded 1% of total volume of cell medium.  
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2.3.5 Cell Harvest 
For all cell harvesting, culture media was aspirated and cells were washed 2x in 
ice cold phosphate-buffered solution (pH 7.4) (PBS). Mammalian Protein Extraction 
Reagent (M-PER) buffer (Pierce) containing protease inhibitor mixture (Calbiochem), 100 
mM phenylmethylsulfonyl fluoride (PMSF), and phosphatase inhibitor II and III mixtures 
(Sigma) were added to the cells at a 1:100 dilution and cells were scraped. Cells in lysis 
buffer were collected and incubated on ice for 10 min to allow lysis to occur. Cell lysates 
were spun down at 16,000 x g to remove nuclear supernatant, and a bicinchoninic acid 
assay (BCA) reaction was carried out to determine protein concentration. 
 
2.3.6 Western Blotting and Co-Immunoprecipitation 
Western blotting and Co-Immunoprecipitation were performed as previously 
described [22]. Cell lysates were prepared with 2x Laemmli sample buffer (Bio-Rad) and 
denatured by boiling for 5 min at 100 °C. Prepared lysates were then loaded onto a 10-
well 10% Tris-glycine gel (Invitrogen) or 18-well, 10% criterion gel (Bio-Rad). After 
running, gels were transferred onto PVDF membranes (Millipore) and blocked for 1 h at 
room temperature with 7% milk.  
Co-Imunoprecipitation cell harvest was achieved in M-PER buffer supplemented 
with protease inhibitor mixture, PMSF, and phosphatase inhibitor II and III mixtures. A 
BCA reaction was performed to determine protein concentration, and the lysates were 
incubated with myocilin antibody by rocking for 4 h to overnight at 4 °C. Next, 50 µL of 
Protein G Dynabeads® (Novex by Life Technologies) were added to the samples and 
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incubated by rocking overnight at 4 °C. Samples were washed with ice-cold PBS and 
loaded onto gels for Western blot analysis. 
 
2.3.7 Triton Solubility 
HEK 293T cells were transfected with either Grp94 siRNA or Control siRNA 24 h 
prior to mutant myocilin transfection. After a 48-h mutant myocilin transfection, cells were 
washed twice with ice-cold PBS and lysed in buffer containing 100 mM Tris-HCl (pH 7.4), 
3 mM EGTA, 5 mM MgCl2, 0.5% Triton X-100, protease inhibitor cocktail Calbiochem), 
and 1 mM PMSF and incubated for 2 minutes on ice. Cells were spun down in a tabletop 
centrifuge at 16,000 x g for 10 min. Supernatant was removed and kept as the Triton 
soluble fraction. The pellet was washed with ice-cold PBS, and then re-suspended in 2x 
Laemmli sample buffer with 9 M urea. The pellet was sonicated and denatured. Soluble 
fractions were prepared with 2x Laemmli sample buffer, denatured, and run on Western 
blot for analysis. 
 
2.3.8 Tetrazolium Assay (MTS) 
Assay is performed using CellTiter 96® Aqueous Non-Radioactive Cell Proliferation 
Assay (Promega) kit. Cells are plated in a 96-well plate, and transfection/drug treatment 
is carried out as previously reported. Manufacturer’s protocol was followed to complete 
assay. Assay is read at 490 nm on a standard plate reader. The tetrazolium in the MTS 
solution will react with live cells to form formazan, which is detectable at 490 nm. The 
more formazan detected, the more viable the cells. 
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2.3.9 Lentiviral Production and Transduction 
Lentiviral vectors were created by sub-cloning c-terminal RFP-tagged cDNA from 
a mammalian expression vector to the pLEX lentiviral vector. Second generation lentiviral 
production required both a packaging plasmid (pPax2) and an envelope plasmid (VSV-
G). Lentiviral vector, packaging plasmid, and envelope plasmid were transfected into HEK 
293T cells using Lipofectamine 2000 transfection reagent (Invitrogen) in serum-free 
media. Cells with transfection reagent were placed in a 37 °C incubator with 5% CO2 for 
4 h. After 4 h, viral supernatant was removed and fresh serum-free media was added to 
the cells. After 48-72 h the media containing viral particles was collected. The virus-
containing media was then centrifuged to remove cell debris, and filtered with a .45 µM 
syringe filter. Virus-containing media was aliquotted and frozen at -80 °C for long-term 
storage. 
For lentiviral transduction, virus-containing media was added to cells in a 1:1 
dilution with complete media. Polybrene (Santa Cruz) was added to the lentiviral mixture 
at 8 µg/mL. HTM cell transduction was achieved after 7 days.  
 
2.3.10 Immunofluorescence and Imaging 
HTM Cells were plated on poly-l-lysine coated coverslips, and transduced with 
RFP-tagged lentivirus, treated as described above. Cells were then fixed in 4% 
paraformaldehyde, permeabilized in 0.1% Triton X-100 in PBS, and glycine-fixed in 0.1% 
glycine in PBS. DAPI was used for a nuclear stain at 1:20,000 dilutions in PBS and 
incubated for 5-10 min. Coverslips were then glued to glass tissue slides using ProLong® 
Gold Antifade Reagent (Invitrogen). Images of cells were taken using the Olympus 
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FV1000 MPE Multiphoton Laser Scanning Microscope. Image analysis of intensity was 
carried out using ImageJ64 software (NIH). 
 
2.3.11 Synthesis 
Synthesis performed by Dr. Brian Blagg’s group at Kansas University. 4-Br-BnIm 
4-bromo-benzylamine (32 μL, 0.26 mmol) was added dropwise to a stirred solution of 
readily available aldehyde [44] (125 mg, 0.26 mmol) in MeOH (2 mL) followed by addition 
of ammonium bicarbonate (20 mg, 0.26 mmol) and dropwise addition of 40% w/v glyoxal 
(29 μL, 0.26 mmol).  The reaction was stirred at 25°C for 12 h.  Upon consumption of the 
starting aldehyde, as seen by thin-layer chromatography, tetrabutylammonium fluoride 
(0.52 mL, 1.0 M solution in THF) was added and the reaction was allowed to stir for an 
additional 30 minutes.  The reaction was then quenched with saturated ammonium 
chloride (5 mL) and then extracted with EtOAc (10 mL x 3).  The organic layers were 
combined, dried over Na2SO4 and concentrated under reduced pressure. The resulting 
residue was subjected to flash chromatography (95:5 CH2Cl2/MeOH) to provide 4-Br-
BnIm as an off white solid (45 mg, 38% yield). 1H NMR (400 MHz, CDCl3/MeOD) 7.45-
7.41 (m, 2 H), 7.00 (d 1.39, 1 H), 6.88 (d 8.37, 2 H), 6.82 (d 1.38, 1 H), 6.45 (s, 1 H), 5.00 
(s, 2 H), 3.86 (s, 3 H), 3.50-3.44 (m, 2 H), 2.88-2.82 (m, 2 H). 13C NMR (500 MHz, 
CDCl3/MeOD) 171.9, 163.5, 159.3, 148.8, 142.6, 136.1, 133.5 (2 C), 129.6 (2 C), 127.6, 
123.5, 121.4, 116.0, 107.3, 104.07, 54.0, 50.4, 32.1, 27.2 HRMS (ESI) calculated for 
C20H19BrClN2O4 (M + H)+ 465.0217, found 465.0237 
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2.3.12 Computational Modeling Based on Co-Crystal Structure 
Molecular docking studies, performed by Dr. Blagg’s group were done using 
Surflex-Dock module in Sybyl v8.0 from Tripos International (St. Louis, Mo). Co-crystal 
structures of radamide bound to Grp94 and yeast Hsp82 were used for docking the 
designed molecules [45]. Visual interpretation and rendering of the images were carried 
out using the PyMOL Molecular Graphics System v1.5.0.4. from Schrödinger, LLC. 
 
2.3.13 Fluorescence Polarization Assays 
Flourescent polarization assays were performed by Dr. Blagg’s group. Increasing 
concentrations of compound were incubated in 96-well plate (black well, black bottom) 
format with recombinant cGrp94 (Enzo Life Sciences, 10 nM) and FITC-labeled 
geldanamycin (Enzo Life Sciences, 6 nM) in assay buffer (20 mM HEPES pH 7.3, 50 mM 
KCl, 5 mM MgCl2, 2 mM DTT, and 20 mM Na2MoO4, 0.01% NP-40, and 0.1 mg/mL BGG) 
at a final volume of 100 μL per well.  Plates were incubated for 24 h at 4 °C.  Fluorescence 
polarization values were measured using excitation and emission filters of 485- and 528-
nm, respectively. Polarization values were then normalized to DMSO (100% tracer 
bound) and apparent Kd values determined using GraphPad Prism software. 
 
2.3.14 Quantification and Statistical Analysis 
Quantification of Western blots was carried out using ImageJ64 software. Graphs 
are plotted based on Intensity Density/Area values. Statistical analysis was performed as 
indicated in the figure legends.  
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2.4 Results: 
2.4.1 Intracellular mutant myocilin levels and toxicity are reduced following Grp94 
knockdown using siRNA. 
We previously showed that Grp94 could regulate the levels of I477N-mutant 
myocilin, but we sought to determine if modulating Grp94 levels could be generalized to 
other disease-associated variants.  HEK cells were transfected with myocilin harboring 
I477N, Y437H, P370L, W286R or N480K substitutions and the effects of Grp94 over-
expression (Fig. 2.1A) or siRNA knockdown (Fig. 2.1B) on their intracellular levels were 
evaluated by Western blot. Over-expression of Grp94 preserved mutant myocilin in cells. 
Conversely, Grp94 knockdown dramatically reduced the levels of each mutant myocilin 
species. Optimal Grp94 knockdown of >60% was achieved with one of 3 siRNAs tested. 
We then fractionated lysates from cells transfected with each myocilin mutant and either 
control or Grp94 siRNA to determine the impact of Grp94 suppression on mutant myocilin 
solubility, as previously described [14, 43]. Briefly, cells were lysed in a buffer containing 
0.5% Triton, centrifuged at 16,000 x g for 10 minutes and supernatant was recovered for 
the “soluble” fraction. The pellet from the spin was re-suspended in loading buffer and 9 
M urea to produce the “insoluble” fraction. Grp94 knockdown reduced both soluble and 
insoluble myocilin species, suggesting, as expected, that Grp94 suppression was 
facilitating myocilin clearance, not forcing it into an insoluble state (Fig. 2.1C&D). 
Quantification was achieved from 4 independent experiments, including those shown in 
figures 2.1B and C. These findings further imply that Grp94 modulation is broadly 
applicable to POAG cases resulting from different myocilin mutations.  
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2.4.2 Improvement of Grp94 inhibitor efficacy through structure-based design. 
We previously determined that the Grp94 inhibitor, BnIm 01, could reduce mutant 
myocilin levels [43]. Based on molecular modeling studies of the pan-Hsp90 inhibitor 
radamide bound to Grp94, Dr. Blagg’s group proposed the imidazole ring as a bioisosteric 
replacement for the cis-amide moiety (Figs. 2.2A&B). Consistent with computational 
predictions, the first compound synthesized, BnIm 01, exhibited ~100:1 selectivity for 
Grp94 versus cytoplasmic Hsp90α/β, as determined by inhibition of Grp94-mediated Toll-
like receptor protein presentation at the cell surface versus Western blot analyses of 
Hsp90-dependent proteins found in the cytoplasm [44]. On the basis of our computational 
model, Dr. Blagg’s group speculated that creating a molecule with increased 
hydrophobicity at the C4-position of the N-benzyl group would improve drug interaction 
with Grp94 and further prevent its interaction with Hsp90 proteins, thereby enhancing 
selectivity [45].  
To test this hypothesis, Dr. Blagg’s group synthesized 4-Br-BnIm (Fig. 2.2A); 
modeling predicts this molecule fits more tightly into the hydrophobic pocket of Grp94 
than the parent BnIm 01 (Fig. 2.2C). While in vitro fluorescence polarization binding 
assays indicate its potency against Grp94 is only slightly increased (1.5 µM with the BnIm 
01 compound compared to 1 µM with the 4-Br-BnIm compound) (Fig. 2.2D), 4-Br-BnIm 
had an approximately 10-fold better effect on I477N mutant myocilin in HEK cells stably 
over-expressing tetracycline-regulatable FLAG-tagged myocilin (iHEK) compared to 
BnIm 01 (Fig. 2.3A&B). This improved potency in cells was likely due to better selectivity 
for Grp94 over other Hsp90 proteins in cells [44]. We observed no changes in Grp78, 
suggesting that ER stress was not activated by either inhibitor [46], nor did we observe 
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an increase in heat shock proteins 27 or 70, indicating that our compound was selectively 
targeting Grp94 over the cytosolic Hsp90 isoforms [47]. We also did not see any change 
in Grp94 expression levels, suggesting that the inhibitors are reversibly binding to Grp94. 
In addition, similar to BnIm 01, 4-Br-BnIm did not cause degradation of other Hsp90-
dependent clients Akt and Ras (Fig. 2.3C)[44]. We then evaluated whether 4-Br-BnIm 
showed improved potency over BnIm 01 against other mutant myocilin species. Indeed, 
4-Br-BnIm had greater efficacy against total myocilin levels of each mutant species tested 
compared to BnIm 01 (Fig. 2.3D).  
 
2.4.3 Grp94 inhibition reduces mutant myocilin levels and toxicity in primary human TM 
cells. 
We next sought to evaluate the efficacy of the selective and potent 4-Br-BnIm in 
primary human TM cells because mutant myocilin is not known to be toxic to cells other 
than TM cells. Lentiviral vectors were generated to express RFP-tagged WT and Y437H 
mutant myocilin, along with RFP only as a control. TM cells were transduced with each 
viral vector for 7 days and subsequently treated with 30 µM BnIm 01, 4-Br-BnIm, or an 
equivalent volume of DMSO (vehicle) for 24 hours. Cells were counterstained with DAPI 
and imaged using confocal microscopy (Fig. 2.4A). Quantification of RFP density 
revealed that BnIm 01 and 4-Br-BnIm significantly reduced Y437H mutant myocilin while 
WT myocilin and the RFP-only vector were largely unaffected by Grp94 inhibition (Fig. 
2.4B). As was the case with the HEK cell system, 4-Br-BnIm resulted in better clearance 
of Y437H-mutant myocilin than did BnIm 01. We then evaluated whether Grp94 inhibition 
could be cytoprotective in TM cells ectopically expressing mutant myocilin using an MTS 
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assay. Y437H, but not WT myocilin, significantly reduced TM cell viability (Fig. 2.4C). 
Impressively, both BnIm 01 and 4-Br-BnIm rescued this toxicity (Fig. 2.4C).   
 
2.4.4 Post-translational modifications render wildtype myocilin a client of Grp94 via 
misfolding. 
In vitro studies have described several ways in which WT myocilin can aggregate 
in the absence of a mutation, raising the possibility that misfolding of WT myocilin could 
be occurring in sporadic cases of POAG, for example by induction of misfolding in relation 
to post-translational modifications.  Impaired glycosylation can prevent protein secretion, 
but it is also known to cause protein misfolding. For myocilin, we predict this misfolding 
could lead to production of early aggregates recognized by Grp94. Therefore, we tested 
the effects of tunicamycin, a reagent known to inhibit N-linked glycosylation [48], on WT 
myocilin and its subsequent ability to associate with Grp94 in cells. Indeed, transiently 
over-expressed WT myocilin, which is not fully secreted [43], did become insoluble in cells 
treated with tunicamycin (Fig. 2.5A), consistent with our cell-free data. Then, using the 
iHEK cell model of WT myocilin over-expression, in which all WT myocilin is secreted, we 
found that Grp94 associated with WT myocilin only in cells treated with tunicamycin, 
further corroborating our in vitro observations (Fig. 2.5B). Conversely, WT myocilin did 
not interact with Grp94 in these cells when treated with brefeldin A (BFA), a chemical that 
blocks ER/Golgi transport and secretion without affecting myocilin folding, further 
suggesting that the effects of tunicamycin on the myocilin/Grp94 interaction are due to 
myocilin misfolding, and not impaired secretion (Fig. 2.5C). Then, using the same iHEK 
cell model of WT myocilin over-expression, we found that tunicamycin blocked myocilin 
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secretion, but this myocilin was sensitized to Grp94 inhibition (Fig. 2.5D&E), further 
suggesting that misfolded myocilin becomes a Grp94 client.  
  
2.5 Discussion: 
Here, we have demonstrated the effectiveness of a second-generation Grp94-
selective inhibitor in clearing a number of POAG-relevant mutant myocilins in several cell 
lines, including, importantly, primary human TM cells. Mechanistically, in vitro studies 
indicate that Grp94 recognizes on-pathway aggregation intermediates, suggesting that 
aberrant quaternary myocilin structure drives Grp94 client recognition rather than 
exposed peptide motifs of individual misfolded or mutant proteins. When forced to misfold, 
WT myocilin becomes an intracellular client of Grp94 that is then sensitized to Grp94 
inhibition. Taken together, our work demonstrates that reducing mutant or aggregated 
WT myocilin via inhibiting its interaction with Grp94 represents a viable therapeutic 
strategy for myocilin-associated forms of glaucoma (Fig. 2.6). 
 Our findings also help explain the paradox of the failure of ERAD to triage 
misfolded myocilin.  Previously, we showed that mutant, but not wildtype, myocilin, was 
recognized by Grp94, and that the degradation rate of mutant myocilin was increased 
when Grp94 was depleted or inhibited [43]. This result was surprising because it 
suggested that Grp94 was interfering with mutant myocilin clearance, rather than 
facilitating its removal through the default ERAD pathway. Grp94 attempts to triage 
mutant myocilin through ERAD but is unsuccessful, leading to its accumulation and mis-
sorting, which results in ER stress [16, 43].  Our current work shows that Grp94 cannot 
triage mutant myocilin through ERAD because it recognizes an already-aggregated state 
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of myocilin, and this association further accelerates aggregation into an amyloid structure 
known to be resistant to resolubilization and refolding. This is not the first time that an 
Hsp90 protein was shown to accelerate the aggregation of an amyloid-prone protein: 
Hsp90α was previously shown to stimulate the aggregation of tau [49]. The evolutionary 
reason for accelerated aggregation by a chaperone protein remains unclear, but one 
possibility is that amyloid fibrils are typically less toxic than amorphous protein aggregates 
[50, 51]. Thus, perhaps chaperones can stimulate amyloid structure to avoid the 
production of amorphous structures that are more prone to non-specific interactions with 
other proteins in the cell. However, in the case of myocilin amyloid, this innate function of 
chaperones triggers an ER stress response, that culminates in TM cell death. Thus, in 
this case, pharmacological inhibition of Grp94 reduces the interaction with aggregated 
myocilin, and, as we showed previously, engages autophagic mechanisms that are better 
equipped for handling protein aggregates while avoiding ER stress activation.   
The BnIm scaffold holds considerable promise for selective Grp94 inhibition 
without significant cellular side effects. New analogs that further exploit the hydrophobic 
pocket occupied by the C4 position are currently under development. Efforts are also 
currently underway to better understand the complex interaction between Grp94 and 
myoc-OLF. Although the N-terminal ATP-binding domain of Grp94 contains the site of 
4-Br-BnIm inhibition, other domains might provide the client protein recognition site; 
inhibition may simply lock Grp94 in a configuration that occludes binding. Such 
structural information could be valuable in developing new inhibitors remote from the N-
terminal ATP binding site. Finally, the cellular mechanisms that lead to clearance of 
myocilin after Grp94 inhibition are still not clear, but once defined, these too could be 
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important targets for therapeutic development against myocilin and allow for a better 
understanding of how aggregated proteins are removed from the ER.   
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Figure 2.1 Consequences of Grp94 knockdown or over-expression on levels of 
intracellular and aggregated mutant myocilin.  A, HEK cells were co-transfected with 
each indicated myocilin mutant and either Grp94 or Control 6TR cDNA. Western blot 
analyses of cell lysates were performed 48 h after cDNA transfection.  B, prior to 
transfection with each myocilin mutant, cells were transfected with either Grp94 or 
Control siRNA. Western blot analysis of cell lysates were performed 72 h following 
siRNA transfection and 48 h after cDNA transfection.  C, prior to transfection with each 
myocilin mutant, cells were transfected with either Grp94 or Control siRNA. Triton 
solubility fractions of cell lysates were analyzed by Western blot. D, Quantification of C 
shows significant reductions in each myocilin mutant caused by Grp94 suppression by 
siRNA as a percent of control siRNA following normalization to loading control. * 
indicates p<0.05. 
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Figure 2.2 Structure, modeling and activity of Grp94 inhibitors.  All inhibitor 
synthesis and binding performed by Dr. Brian Blagg’s Lab at Kansas University. A, 
Structures of radamide, BnIm 01 and 4-Br-BnIm. B, BnIm 01 docked in a hydrophobic 
pocket within the ATP binding site of Grp94 (based on radamide-bound structure, PDB: 
2GFD). C, 4-Br-BnIm docked in Grp94 shows how the hydrophobic pocket can be 
occupied with the hydrophobic substitution at C4 (indicated by arrow), which likely 
improves specificity. D, Fluorescence polarization (FP) assay of recombinant Grp94 
pre-incubated with FITC-labeled geldanamycin and then increasing concentrations of 
each compound. Plates were incubated for 24h and FP measured at 485 ex and 528 
em. FP values were normalized to DMSO (100% tracer bound). 
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Figure 2.3 Effects of specific Grp94 inhibitors on levels of intracellular mutant 
myocilin. A, Western blot analysis of HEK cells stably over-expressing tetracycline-
regulatable FLAG-tagged I477N mutant myocilin lysates and treated with indicated 
doses of BnIm 01 or 4-Br-BnIm for 24 h. Western blots were probed for myocilin levels, 
as well as levels of other heat-shock proteins (Hsp27, Hsp70) and ER chaperones 
(Grp78, Grp94).  B, Quantification of A shows the half maximal effective concentration 
(EC50) of BnIm 01 and 4-Br-BnIm for reducing mutant myocilin. C, Western blot 
analysis of HEK cells stably over-expressing tetracycline-regulatable FLAG-tagged 
I477N mutant myocilin lysates and treated with indicated doses of 4-Br-BnIm for 24 h. 
Akt and Ras levels were unaffected by treatment.  D, Western blot of lysates from HEK 
cells transiently overexpressing five forms of mutant myocilin and treated with 30 µM 
BnIm 01, 4-Br-BnIm, or equivalent volume of vehicle (Veh/DMSO) for 24 h. 
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Figure 2.4 Grp94 inhibitors reduce mutant myocilin levels and toxicity in HTM 
cells. A, Immunofluorescence imaging of human trabecular meshwork (HTM) cells 
transduced with RFP-tagged lentivirus expressing RFP control, RFP-tagged WT 
myocilin, or RFP-tagged Y437H myocilin and treated with 30 µM BnIm 01, 4-Br-BnIm, or 
equivalent volume of DMSO vehicle. Myocilin is shown in red and the nuclear marker 
DAPI shown in blue (40x magnification). B, Quantification of immunofluorescence 
images detecting RFP density ± standard deviation (n=3). Significance was measured 
using the student’s t test; * indicates p<.05, ** indicates p<0.01. C, MTS assay of HTM 
cells overexpressing WT or Y437H myocilin following treatment with 30 µM BnIm 01, 4-
Br-BnIm, or vehicle equivalent (DMSO) for 6 h. Cell viability is shown prior to treatment 
(Pre-Tx) and following treatment (Post-Tx) ± standard deviation (n=3). Significance was 
measured using the student’s t test; * indicates p<.05, ** indicates p<0.01.  
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Figure 2.5 WT myocilin becomes a client of Grp94 when myocilin is misfolded. A, 
Western blot analysis of Triton soluble/insoluble fractions from iHEK WT myocilin cell 
lysates treated with 6µM tunicamycin for 24 h. B, Co-IP of myocilin and subsequent 
Western blot analysis of iHEK WT myocilin cell lysates treated with 6µM concentration 
of tunicamycin; Inputs indicates Western blot of lysates without co-IP. C, Co-IP of 
myocilin and subsequent Western blot analysis of iHEK WT myocilin cell lysates treated 
with 3µM concentration of Brefeldin A; Inputs indicates Western blot of lysates without 
co-IP. D, Western blot analysis of iHEK WT myocilin cells treated with 6µM 
concentration of tunicamycin followed by a dose response of BnIm 01, 4-Br-BnIm, or 
equivalent volume of DMSO vehicle. E, Quantification of Western blot analysis on dose 
response from D showing myocilin levels as a percent of vehicle following normalization 
to loading control (Gapdh). 
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Figure 2.6 Grp94 accelerates myocilin aggregation, a process that can be 
prevented by Grp94 inhibition. Myocilin misfolding causes it to form small aggregates 
that bind Grp94. Grp94 facilitates amyloid formation, preventing clearance of myocilin 
and causing toxicity. Grp94 inhibitors prevent Grp94 from interacting with myocilin, 
allowing a secondary autophagic pathway to facilitate clearance. 
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Chapter Three: 
Topical Ocular Administration of a Selective Grp94 Inhibitor Rescues Functional 
Toxicities in a Mouse Model of Hereditary Primary Open Angle Glaucoma 
 
3.1 Abstract 
Over 70 mutations in exon 3 of the MYOC (myocilin) gene have been linked to 
development of primary open-angle glaucoma (POAG). This genetic link has led many 
to believe myocilin plays a vital role in both disease initiation and progression. Recent 
work has demonstrated a direct interaction between mutant forms of myocilin and the 
Hsp90 homolog, Grp94. This interaction preserved mutant myocilin within the 
endoplasmic reticulum (ER) of trabecular meshwork (TM) cells, precipitating TM cell 
dysfunction and downstream glaucomatous pathology. Here, we report the treatment of 
myocilin-associated glaucomatous pathology in the Tg-MYOCY437H mouse model 
through topical ocular administration of the specific Grp94 inhibitor, 4Br-BnIm. Following 
chronic treatment with 4Br-BnIm, we observed a rescue of multiple pathologies 
commonly associated with myocilin-induced glaucoma, including elevated intraocular 
pressure, myocilin accumulation in the TM, reduced scotopic and photopic visual 
responses, and retinal ganglion cell death. These results demonstrate the validity of 
targeted Grp94 inhibition as a novel disease-modifying treatment for patients with 
POAG.  
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3.2 Introduction 
Primary open-angle glaucoma (POAG) is a neurodegenerative optic neuropathy, 
characterized by progressive irreversible vision loss [31] [52] [53] [54] [55]. Mutations in 
the myocilin gene (MYOC) are the most common genetic link to clinical cases of POAG, 
including the less common but more aggressive juvenile-onset open-angle glaucoma 
(JOAG) [56]. There are over 70 documented MYOC mutations that have been linked 
with glaucomatous pathology. Recent studies have shown that MYOC mutations lead to 
a protein product that readily misfolds and accumulates within the endoplasmic 
reticulum (ER) of trabecular meshwork (TM) cells [5, 8, 9, 14]. This accumulation 
causes TM cell dysfunction, leading to reduced aqueous humor outflow, elevated 
intraocular pressure (IOP), retinal ganglion cell (RGC) dysfunction, and loss of optic 
nerve (ON) axons [57].  
 Clinically, treatment of POAG is best initiated when diagnosed early in the 
disease progression. For patients with POAG, initial treatment options include 
pharmaceuticals, such as alpha agonists, beta blockers, and prostaglandin analogs, to 
reduce aqueous humor production at the ciliary body (CB) and promote alternative 
outflow pathways [58] [59] [60] [61]. As the disease continually progresses, more 
substantial surgical filtration therapies become necessary, such as sclerectomy or 
trabeculectomy [62] [63] [64] [65]. While these therapies have proven to be effective at 
reducing IOP and slowing progression of the disease, they are merely palliative in 
nature and do not prevent the disease endpoint of irreversible blindness. To develop a 
curative therapy, the underlying disease mechanisms must be targeted; however, this 
has proven to be difficult, as a defined disease mechanism still remains a mystery. 
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Our previous work has explored this disease mechanism and discovered a link 
between mutant or misfolded forms of myocilin and the ER-associated Hsp90 homolog 
glucose-regulated protein 94 (Grp94). We have shown that Grp94 recognition of 
mutant/misfolded myocilin preserves the protein within the ER of TM cells, leading to 
protein accumulation and aggregation, precipitating TM cell dysfunction [43,54]. When 
the Grp94-misfolded myocilin interaction is inhibited, whether through gene knockdown 
or pharmacological inhibition, the TM cell machinery regains the functional ability to 
degrade and remove the misfolded protein, likely through a robust autophagic 
mechanism [43, 54]. This has led us to hypothesize that Grp94 is directly responsible 
for mutant myocilin pathology in POAG.  
The current study initially investigated the myocilin interactome following 
treatment with the Grp94 specific inhibitor 4Br-BnIm in cells to determine pathways 
associated with myocilin triage following Grp94 inhibition. The efficacy of this compound 
in vivo was then explored using topical ocular administration to evaluate glaucomatous 
pathologies in these mice such as IOP, RGC function, and myocilin accumulation. Our 
results indicate the validity of specific Grp94 inhibition as a potential first curative 
therapeutic for patients suffering from myocilin-associated POAG. 
 
3.3 Materials and Methods 
3.3.1 Inhibitor synthesis 
4Br-BnIm was synthesized and provided by Dr. Brian Blagg’s group at the 
University of Kansas as previously described [54].  
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3.3.2 Study Approval 
All institutional guidelines for the care and use of animals were followed. All 
animal handling and procedures were carried out in accordance with the University of 
South Florida’s Institutional Animal Care and Use Committee (IACUC) in accordance 
with the Association for Assessment and Accreditation of Laboratory Animal Care 
International (AALAC) regulations. 
 
3.3.3 Animal Husbandry 
The transgenic-Y437H mouse model (Tg-MYOCY437H) was a generous gift from 
Val Sheffield at the University of Iowa. Characterization of the Tg-MYOCY437H mouse 
was previously described [16,18]. Mice were housed and bred at the University of South 
Florida Byrd Alzheimer’s Institute onto the C57BL/6 background. Mice heterozygous for 
the Tg-MYOCY437H mutation were bred together to produce a 1:2:1 ratio of homozygous 
transgenic: heterozygous transgenic: wild type littermates.  Heterozygous littermates 
were maintained for breeding, and homozygous transgenic and wild type littermates 
were used for the study. Genotyping for the transgene was performed as previously 
described by the Sheffield Lab [16,18].  
 
3.3.4 Cell culture  
Cell culture was performed as previously described [43]. Stably transfected iHEK 
cells expressing I477N mutant myocilin were grown and maintained in Dulbecco’s 
Modified Eagle’s Medium supplemented with 10% FBS (Invitrogen), penicillin (100 
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units/ml), streptomycin (100 mg/ml) and 1% GlutaMAX (Invitrogen) at 37C under 5% 
CO2. For cell selection, the cells were supplemented with hygromycin B (200 mg/ml) 
(InvivoGen) and G418 (100 mg/ml) (Gibco). To induce myocilin expression in these 
cells, they were treated with 5 mg/ml tetracycline 24 h prior to transfection, or 48 h prior 
to pharmacological treatment. 
 
3.3.5 Antibodies (cell culture) 
Myocilin polyclonal antibody (1:1500) was a generous gift from W.D. Stamer at 
Duke University [150]. Actin antibody (1:1000) was purchased from Sigma (A5316). 
Secondary antibodies for western blots were all HRP-linked and purchased from 
Southern Biotechnologies (Birmingham, AL). Primary and secondary antibodies were 
added to western blots at a 1:1000 dilution in 7% milk. 
 
3.3.6 Pharmacological treatment (cell) 
Grp94 inhibitors were solubilized in DMSO (Sigma Aldrich), and added to cells at 
the indicated concentrations. All drug treatments were carried out 24h prior to cell 
harvest, and DMSO concentration never exceeded 1% of total volume of cell medium.  
 
3.3.7 Cell Harvest 
Cell harvest was performed as previously described [54]. Culture medium was 
aspirated and cells were washed 2× in ice cold phosphate-buffered solution (pH 7.4) 
(PBS). Mammalian Protein Extraction Reagent (M-PER) buffer (Pierce) containing 
protease inhibitor mixture (Calbiochem), 100 mM phenylmethylsulfonyl fluoride (PMSF) 
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and phosphatase inhibitor II and III mixtures (Sigma) were added to the cells at a 1:100 
dilution and cells were scraped. Cells in lysis buffer were collected and incubated on ice 
for 10 min to facilitate lysis. Cell lysates were spun down at 16000xg for 10min and a 
bicinchoninic acid assay (BCA) reaction was carried out to determine protein 
concentration for biochemical assessment of protein abundance.  
 
3.3.8 Western blotting (cell) 
Western blotting was performed as previously described [22]. After gel run was 
complete, gels were transferred onto PVDF membrane (Millipore) at 100 volts for 1 
hour. After transfer, blots were blocked with 7% milk in TBS for 1 hour at room 
temperature before addition of primary antibody.  
 
3.3.9 Inhibitor pharmacokinetics 
PK studies performed by Dr. Brian Blagg’s group at Kansas University. Wild type 
C57BL/6 mice were treated with topically administered 4Br-BnIm (~10 µL) at 100 µM 
concentration. Eye drop remained on mouse eye for 1 minute before being irrigated off 
with sterile PBS. Mice were then immediately euthanized, eyes enucleated, and flash 
frozen. Isolated eye samples were diluted (0.1g/g in water) then homogenized by 
vortexing in the presence of glass beads. Organics were extracted using EtOAc. 
Following removal of EtOAc by evaporation, samples were diluted in MeCN/H2O (1:1) for 
HPLC analysis. Concentrations of samples were determined after generating a standard 
curve for 4Br-BnIm at known concentrations. HPLC Conditions: Agilent 1100 series 
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quaternary pump, 1.0 mL/min, 50% MeCN/50% H2O, detection at 254nm. Column: 
Agilent C-18 column, 4.6x150mm, 5µm. Rt = 6.5 min. 
 
3.3.10 Inhibitor application and study duration 
4Br-BnIm dose concentration was determined by HPLC PK analysis observing 
concentration of drug to cross the corneal epithelial barrier when applied topically. 
Approximately 10% of the compound readily crossed the eye, therefore 300 µM stocks 
were made up, which ensured a concentration of 30 µM would contact intraocular 
tissues in the anterior chamber. Drugs were solubilized in DMSO and diluted in sterile 
saline, so that the concentration of DMSO was 1%. Once a day, mice were restrained 
and 1 drop (~10 µL) of drug was applied topically via eye drop. The drop was allowed to 
sit on the eye for 1 minute before the mouse was returned to its cage. Mice were treated 
1x/day for 14 weeks.  
 
3.3.11 Intraocular Pressure (IOP) Measurements 
Intraocular pressure (IOP) levels in the mouse eye were obtained using the Icare 
TonoLab rebound tonometer (Icare, Finland). Bi-weekly, mice were briefly anesthetized 
with Isoflourane at a 3-4% flow rate. Once induced, mice were quickly placed in a tube 
restraint, and 6 IOP measurements were taken per eye. The 6 measurements were 
then analyzed to determine standard deviation to determine consistency of the 
measurements. If the standard deviation was within the parameters determined by the 
machine, the mouse was removed from the restraints and returned to its cage. Animals 
were anesthetized for no more than 2 minutes during the IOP measurement process.  
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3.3.12 Electrophysiology 
Electroretinograms (ERGs) were recorded from both eyes of each mouse post-
treatment in a lightproof/soundproof booth. Animals were dark adapted for 24 hours 
prior to data collection. Prior to ERG recordings, mice were anesthetized using a 
Ketamine (100 mg/kg) and Acepromazine (1 mg/kg) mixture delivered via 
intraperitoneal (IP) injection. Mouse health and vitals were monitored visually 
throughout the experiment, with additional anesthesia given as needed. A custom ring-
shaped gold electrode was placed on the corneal limbus of each eye. Platinum needle 
electrodes (Natus Neurology Inc., Warwick, RI) inserted in the temples and tail served 
as references and ground readings, respectively. Recorded signals were differentially 
amplified (2000x) and filtered (0.1-1000 Hz) by a multi-channel bio-amplifier (Xcell-3x4, 
FHC Inc., Bowdoin, ME) and digitized at 1000 Hz. Light stimuli were produced by a 
green LED (Vishay TLCTG5800, Newark Electronics, Palatine, IL) with an 8o emittance 
angle positioned 1 cm perpendicularly to each cornea. The LEDs had a peak 
wavelength of 520 nm and peak output of 2100 cd/m2 measured with a calibrated 
photometer (UDT Instruments Inc., Baltimore, MD). Full-field scotopic ERGs (n35-p50) 
were recorded for a series of 200 brief (10ms) flashes (1.32 log cd·s/m2) delivered to 
both eyes simultaneously. LED light intensity was gradually increased to determine 
lowest possible intensity to evoke an ERG response. After scotopic recording, mice 
were exposed for 30 min to ambient room light (15 cd/m2) from an LED strip that lined 
the booth ceiling. After light-adaption, full-field photopic ERGs (p50-n95) were recorded. 
LED flash sequences were separated by a 3 second interval, to allow sufficient time for 
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mice to fully recover from the previous LED flash, ensuring validity of ERG recordings. 
Light-evoked signals were quantified in terms of scotopic (n35-p50)/photopic (p50-n95) 
wave amplitude. Wave amplitudes were measured from the trough-to-peak (n35-p50) or 
peak-to-trough (p50-n95). Statistical analysis was performed using SigmaPlot 13.0 
software (San Jose, CA) and graphs were generated with GraphPad Prism 5.0 
software. 
 
3.3.13 Eye enucleation  
Mice were euthanatized with a .2% Somnasol (50 mg/kg) in saline solution. Eyes 
were gently removed from the skull preserving the morphology of the eye globe. Once 
removed from the skull, eyes were either fixed in Davidson’s (1:3:2:3, glacial acetic acid: 
95% ethanol, 10% neutral buffered formalin, distilled water) solution for histology, or 
micro-dissected to remove the retinas.  
 
3.3.14 Whole retinal mount 
Post-enucleation, mouse eyes were micro-dissected to remove the intact retina. 
Eyes were placed in an isotonic solution, and the cornea was removed using surgical 
micro-scissors. The iris was gently pulled away from the lens, and the lens was 
removed using tweezers. The remaining eye cup contained the retina and sclera. 
Gently, the retina was peeled away from the sclera, producing a whole intact retina. 
Retinas were placed in 10% neural buffered formalin for fixation for 48 hours and then 
moved to a dPBS+ Sodium Azide solution for storage until tissue staining.   
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3.3.15 Histological processing of mouse eye tissue 
Enucleated mouse eyes were immediately fixed in Davidson’s Solution for 48 
hours. Davidson’s solution was used to maintain good nuclear detail without formalin 
pigmenting. After 48 hour fixation, eyes were switched to 10% neutral buffered formalin 
for shipping. Fixed eyes were shipped to HistoWiz Inc. (Brooklyn, NY, USA) where 
tissue was processed, paraffin embedded, sectioned, and mounted on slides. Sections 
were cut longitudinally at a thickness of 10 microns. Slides were returned to our lab for 
deparaffinization and tissue staining. 
 
3.3.16 Tissue deparaffinization/rehydration  
Modified from an existing Abcam protocol (www.abcam.com/protocols/ihc-
deparaffinization-protocol). Slides were placed in a glass slide rack, and 
deparaffinized/rehydrated using the following steps: 2x 3min wash in Xylenes, 1x 3min 
wash in 1:1 Xylenes:100% ethanol, 2x 3min wash in 100% ethanol, 1x 3min wash in 
95% ethanol, 1x 3min wash in 75% ethanol, 1x 3 min wash in 50% ethanol, keep in 
ddH2O until antigen retrieval. After rehydration, at no point were the slides/tissue 
allowed to dry out.  
 
3.3.17 Antigen Retrieval 
After deparaffinization, slides were submersed in a Sodium Citrate Buffer (10mM 
Sodium Citrate, 0.05% Tween 20, ph 6.0) in a microwave safe plastic coplin jar. The 
coplin jar was placed in a water bath, to maintain a constant temperature, and 
microwaved at 2 minute increments, replacing water and sodium citrate butter after 
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each heating cycle. This process was repeated three times, ensuring heat-induced 
epitope retrieval.  
 
3.3.18 Tissue staining 
After deparaffinization and antigen retrieval, whole eye section slides were 
fluorescently stained as previously described [67]. Briefly, following permeabilization, 
tissue was incubated with myocilin (Santa Cruz (21243), Dallas, TX, 1:50) primary 
antibody overnight. The following day, sections underwent PBS washing, and tissue 
was incubated with Alexa Fluor 594 donkey anti-goat IgG (Invitrogen (11058), Grand 
Island, NY; 1:500) secondary antibody for 2 hours.  
For whole mount retinas, tissue sections were free-floating fluorescently stained 
as previously described above. Briefly, following permeabilization, tissue was incubated 
with γ-synuclein (Abcam (55424), Cambridge, UK, 1:1000) primary antibody overnight. 
The following day, sections underwent PBS washing, and tissue was incubated with 
Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen (11008), 1:1000) secondary antibody for 
2 hours. Whole retinas were mounted and both whole eye and whole retina slides were 
cover slipped using ProLong Gold Antifade Reagent (Invitrogen).  
 
3.3.19 Tissue imaging, quantification, and analysis 
Both myocilin stained whole eye sections and γ-synuclein stained whole retinas 
were imaged using the Olympus FV1200 MPE Multiphoton Laser Scanning Microscope 
using a 40x objective (scale bar = 40 µM). All fluorescent quantification was carried out 
using ImageJ analysis software (National Institutes of Health). Myocilin was quantified in 
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the TM of whole eye slices for fluorescence intensity. Gamma-synuclein was quantified 
for the entire retina section for both fluorescence intensity, and positively stained cells. 
To determine positively stained cells, a fluorescence threshold was determined. Particle 
analysis was performed on areas between 0 and infinity pixels2 and a circularity of 0.00-
1.00, which allowed for the analysis of all positive gamma-synuclein staining. For whole 
eye sections, each mouse had 2 TMs analyzed. These values were then averaged to 
determine average myocilin levels in each mice. For whole mount retinas, analysis was 
taken of the retina as a whole, measuring total number of positive cells and intensity of 
positively stained cells.  
 
3.3.20 Quantification and Statistical Analysis 
Statistical analysis of IOP, ERG, and fluorescent images was performed using 
student’s t-test, comparing each individual treatment group. Values were considered 
significant if p<0.05. Graphs were generated using GraphPad Prism 5.0 analysis 
software. 
 
3.4 Results 
3.4.1 The selective Grp94 antagonist 4Br-BnIm triages mutant myocilin and possesses 
trans-scleral permeability   
We have previously shown that the specific Grp94 inhibitor, 4Br-BnIm, was 
effective at clearing intracellular mutant myocilin, inhibiting in vitro myocilin protein 
aggregation, and alleviating TM cell dysfunction [54]. To properly translate these results 
to an in vivo mouse model for glaucoma, we set out to determine if 4Br-BnIm would be 
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effective as an ocular treatment (Fig. 3.1A). First, to confirm intracellular mutant myocilin 
reduction by 4Br-BnIm treatment, iHEK cells overexpressing I477N mutant myocilin 
were treated with increasing concentrations of 4Br-BnIm, and intracellular myocilin 
levels were evaluated by western blot (Fig. 3.1B). Densitometry quantification revealed 
4Br-BnIm reduced intracellular mutant myocilin levels, with almost 50% reduction at a 
30 µM concentration (Fig. 3.1C).  
However, to definitively determine the effectiveness of this compound as a 
topical ocular treatment, the pharmacokinetic (PK) efficiency of crossing the corneal 
epithelial barrier when applied topically was tested. PK studies performed by Dr. Brian 
Blagg’s Lab at Kansas University. One drop (~10 uL) of 4Br-BnIm was applied to the 
eye and allowed to permeate for 1 minute. Mouse eyes were subsequently harvested, 
homogenized and analyzed through high performance liquid chromatography (HPLC) to 
determine the intraocular concentration of the compound. Quantification of these results 
revealed 13.1±2.7% of 4Br-BnIm could effectively cross the corneal epithelial barrier. 
These data demonstrated that 4Br-BnIm was a viable candidate for topical ocular 
administration, as the bioavailability of current ophthalmic medications is considered 
acceptable at a rate of approximately 5% [68].Therefore, we determined a dose of 300 
uM, with approximately 10% of the compound effectively crossing the corneal epithelial 
barrier, would ensure approximately a 30 µM concentration of 4Br-BnIm was reaching 
intraocular tissues in the anterior chamber of the eye when applied topically.  
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3.4.2 Intraocular pressure elevation in Tg-MYOCY437H mice is rescued by topical ocular 
treatment with 4Br-BnIm 
In our previous in vitro work, we showed that inhibition of Grp94 association with 
misfolded or mutant myocilin was sufficient to induce intracellular protein clearance [43] 
[54]. Therefore, we sought to determine if this could be translated to pathology reduction 
in vivo in the Tg-MYOCY437H mouse model of glaucoma. Mice were aged to 4 months to 
ensure the development of pathology, and then separated into 4 distinct treatment 
groups: wild–type (WT) + vehicle (n=6), WT + 4Br-BnIm (n=6), transgenic (Tg) + vehicle 
(n=12), and Tg + 4Br-BnIm (n=14). Animals received daily topical ocular treatment as 
described in the methods. Bi-weekly, IOP measurements were recorded on each 
individual eye (Fig. 3.2A). Baseline readings for the WT mice were measured at 13.83 ± 
.55 and 13.5 ± .70 mm Hg for the vehicle and 4Br-BnIm groups, respectively. Baseline 
readings for the Tg mice were measured at 19.17 ± .61 and 19.86 ± .43 mm Hg for the 
vehicle and 4Br-BnIm treated groups, respectively. There was no significant difference 
between transgenic treatment groups prior to treatment phase (p=.3721) (Fig. 3.3B). 
Post-treatment IOP readings for WT mice were measured at 12.83 ± .28 and 13.17 ± 
.28 mm Hg for the vehicle and 4Br-BnIm treated groups, respectively. Post-treatment 
readings for Tg mice were measured at 17.5 ± .28 and 14.0 ± .34 mm Hg for the vehicle 
and 4Br-BnIm treated groups, respectively. Tg mice treated with vehicle had 
significantly higher IOP readings than Tg mice treated with 4Br-BnIm following the 
treatment period (p=.0001)(Fig. 3.2B). These findings imply that topical ocular treatment 
of 4Br-BnIm is sufficient to reduce elevated IOP levels in the Tg-MYOCY437H mouse 
model of glaucoma. 
54 
 
 
3.4.3 Myocilin accumulation in the trabecular meshwork of Tg-MYOCY437H mice is 
reduced following topical ocular treatment with 4Br-BnIm 
As we have previously shown, 4Br-BnIm is effective at reducing intracellular 
levels of mutant myocilin in in vitro primary TM cell models [54]. To determine if 4Br-
BnIm had the same effect in the Tg-MYOCY437H mouse model, we performed 
immunohistological staining of myocilin in the TM (Fig. 3.3A). Quantification of 
immunostaining for fluorescent intensity revealed no significant difference in myocilin 
levels when comparing WT + vehicle (n=4) and WT + 4Br-BnIm (n=6) treatment groups 
(p=.9588) (Fig. 3.3B). This allowed us to group all WT mice together for comparison 
with Tg-MYOCY437H treatment groups. Tg-MYOCY437H + vehicle (n=14) mice had 
significantly more myocilin accumulation in the TM compared to WT mice (p=.0002). 
Importantly, Tg-MYOCY437H + 4Br-BnIm (n=10) mice showed no significant difference in 
myocilin levels in the TM compared to WT mice (p=.5933) (Fig. 3.3C). Collectively, 
these data indicate that topical ocular administration of 4Br-BnIm had a profound effect 
on TM tissue in Tg-MYOCY437H mice, further validating 4Br-BnIm as a viable therapeutic 
targeting pathology associated with POAG.  
 
3.4.4 Scotopic and photopic vision is preserved in Tg-MYOCY437H mice following topical 
ocular treatment with 4Br-BnIm 
In order to determine retinal cell health, we evaluated the scotopic visual 
response of Tg-MYOCY437H mice, using dark-adapted electroretinography (ERG). Mice 
were dark adapted for 24 hours prior to ERG readings. Representative tracings of dark-
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adapted ERG show scotopic (n-35-p50) wave amplitudes (Fig. 3.4A). Quantification of 
these dark-adapted ERG tracings showed no significant difference between WT 
treatment groups n35-p50 wave amplitudes (p=.8255) (Fig. 3.4B). As previously 
reported [18], Tg mice treated with vehicle had significantly reduced n35-p50 wave 
amplitudes compared to WT mice (p=.0134). However, Tg mice treated with 4Br-BnIm 
displayed no significant difference in n35-p50 wave amplitudes compared to WT mice 
(p=.3652) (Fig. 3.4C), once again demonstrating the effectiveness of the compound.  
To determine the photopic visual response of Tg-MYOCY437H mice, we performed 
light-adapted ERG, exposing the mice to ambient room light for 30 minutes following 
dark-adapted ERG recordings. Representative tracings of light-adapted ERG photopic 
(p50-n95) wave amplitudes are depicted in Fig. 3.4D. Quantification of these light-
adapted ERG tracings showed no significant difference between WT treatment groups 
p50-n95 wave amplitudes (p=.6850) (Fig. 3.4E). Similar to the scotopic response, Tg 
mice treated with vehicle displayed significantly reduced p50-n95 wave amplitudes 
compared to WT mice (p=.0140). Again, Tg mice treated with 4Br-BnIm had no 
significant difference in p50-n95 wave amplitudes compared to WT mice (p=.5310) (Fig. 
3.5F). These data suggest that topical ocular administration of 4Br-BnIm can preserve 
both scotopic and photopic visual responses, thus effectively preserving retinal neuronal 
cell activation. 
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3.4.5 Retinal ganglion cell viability is preserved in Tg-MYOCY437H mice following topical 
ocular treatment with 4Br-BnIm 
RGC viability was evaluated by whole-mount γ-synuclein staining of mouse 
retinas comparing WT mice to each Tg treatment group. First, total RGC cell count was 
determined using ImageJ software to quantify the number of positive cells (Fig. 3.5A). 
Quantification showed a significant reduction (69%) in positively stained RGC cells in Tg 
mice treated with vehicle as compared to WT mice (p=.0002). There was no significant 
difference between Tg mice treated with 4Br-BnIm and WT mice (p=.7945) (Fig. 3.5B). 
Next we looked at intensity of fluorescent γ-synuclein staining to determine overall 
viability of healthy RGCs (Fig. 3.5C). Quantification showed a significant reduction in 
fluorescent intensity (90%) in Tg mice treated with vehicle as compared to WT mice 
(p=.0023). There was no significant difference in fluorescent intensity of γ-synuclein 
staining in Tg mice treated with 4Br-BnIm compared to WT mice (p=.5846) (Fig. 3.5D). 
These findings, taken together with the ERG data, suggest that topical ocular treatment 
with 4Br-BnIm preserved retinal cell health and function in the Tg-MYOCY437H mouse 
model, allowing normal signal transduction and conversion of light waves into visual 
signals in the visual cortex of the brain.  
 
3.5 Discussion 
Here, we have further validated specific Grp94 inhibition as a viable therapy for 
treating myocilin-associated POAG by restoring TM cell function and reducing 
glaucomatous pathology in the Tg-MYOCY437H mouse model. Previously, we have 
shown that specific Grp94 inhibition leads to a reduction in myocilin accumulation and 
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cellular dysfunction in primary human TM cells [54]. Additionally, we have shown that in 
vitro myocilin aggregation is significantly reduced following protein incubation with 4Br-
BnIm [54].  The current study demonstrated that these previous in vitro cell and protein 
assay results translate to effective in vivo treatment of myocilin-associated POAG 
pathologies. These findings underscore the potential therapeutic benefit of specific 
Grp94 inhibition as a treatment for patients with myocilin-associated POAG and further 
define a specific disease mechanism of POAG pathology. The results from the mass 
spectrometry also elucidate the intracellular mechanisms of mutant myocilin 
degradation, which will provide valuable insight into Grp94-mediated myocilin triage. 
 TM tissue is the main component of the conventional outflow pathways of 
aqueous humor. Several studies have shown that accumulation of myocilin in the TM 
precipitates TM cellular dysfunction [16, 18, 54, 77], leading to the pathologies 
commonly associated with POAG, including increased IOP, RGC cell death, and 
eventually irreversible blindness. Therefore, if effective, by reducing mutant myocilin 
accumulation in the TM, normal TM cell function can be restored in the human eye, 
preventing downstream POAG pathologies from being initiated. Here, we have shown 
that topical ocular administration of 4Br-BnIm significantly reduced myocilin levels in the 
TM. This suggests that specific Grp94 inhibition is a viable method for restoring normal 
TM cell function in patients with POAG.  
The functional pathologies associated with myocilin-induced POAG include 
elevated IOP, diminished scotopic/photopic visual responses, and deterioration of RGC 
health/function. Importantly, topical ocular administration of 4Br-BnIm led to a significant 
reduction in each of these functional pathologies, demonstrating its broad therapeutic 
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utility. The effectiveness and potency of specific Grp94 inhibition as a viable treatment 
for POAG pathologies also highlights the vital role Grp94 plays in POAG disease 
progression. Prior to our work, Grp94 was mainly studied for its pro-oncogenic 
properties as it relates to cancer development [78-80]. Specifically, how elevated levels 
of Grp94 are a molecular hallmark of tumor metastasis [81-83]. With Grp94’s clear 
involvement in other degenerative diseases, it would be prudent to further explore non-
primary open-angle forms of glaucoma, including closed-angle and secondary 
glaucoma, to determine what role, if any, Grp94 plays in their disease progression. 
 In conclusion, this study revealed the effectiveness and potency of specific 
Grp94 inhibition as a viable treatment method for POAG. Autophagic degradation of 
mutant myocilin following specific Grp94 inhibition leads to restoration of TM cell 
function, reduced IOP, and preserved retinal cell function, ultimately restoring health 
and function of the eye (Fig. 3.6). Grp94 inhibition holds considerable promise as a 
potential disease-modifying treatment of POAG. New compounds that are more potent 
at reducing intracellular myocilin at lower concentrations, while also readily crossing the 
corneal epithelial barrier are currently under development. Efforts are also currently 
underway to determine the most effective means of drug delivery into the eye, to target 
TM cells while reducing off-target effects. Although topical ocular administration 
provided significant reductions in pathologies associated with POAG, other means of 
delivery, such as anterior chamber micro-injections, could prove to be more effective at 
directly targeting the TM. Studies exploring potency, bioavailability, means of delivery, 
and disease mechanism will be vital in progressing this research into human clinical 
trials and developing an effective treatment for patients with POAG.  
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Figure 3.1 4Br-BnIm reduces intracellular mutant myocilin. (A) Structure of specific 
Grp94 inhibitor, 4Br-BnIm. (B) Tetracycline-inducible Hek cells (iHEK) overexpressing 
the disease-associated I477N mutant myocilin were treated with increasing doses of 
4Br-BnIm to determine a dose response. Western blot analysis of cell lysates were 
performed 24 h after drug treatment. (C) Quantification of (B) shows effective reduction 
of intracellular mutant myocilin when treated with 4Br-BnIm. 
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Figure 3.2 Topical ocular 4Br-BnIm reduces intraocular pressure in Tg-
MYOCY437H mice. (A) Intraocular pressure (IOP) levels as recorded by rebound 
tonometry for four treatment groups (WT + vehicle (n=6), WT+Grp94 Inhibitor (n=6), Tg 
+ vehicle (n=12), Tg+Grp94 Inhibitor (n=14)). Readings were recorded every two weeks 
throughout the treatment period. Time=0 represents the IOP of animals prior to 
treatment initiation. Treatment period began at age=4 months, and occurred 1x/day for 
the duration of the study. (B) Quantification of (A) comparing average IOP levels of the 
four treatment groups pre- and post- treatment cycle. Initially, there was no statistical 
difference between Tg groups prior to treatment (p=.3721) (19.2 to 19.9 mmHg). 
However, after the treatment period we observed a significant reduction in IOP for the 
Tg+Grp94 Inhibitor group compared to Tg + vehicle group (p=<.0001) (14.0 to 17.5 
mmHg), returning to levels consistent with both WT treatment groups (13mmHg). 
Statistical analysis carried out using two-tailed t-test. *P<.05, **P<.001, ***P<.0001. 
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Figure 3.3 Topical ocular 4Br-BnIm reduces intracellular myocilin accumulation in 
the TM of Tg-MYOCY437H mice. (A) Representative images showing myocilin (Santa 
Cruz (21243)) accumulation in the TM of WT and Tg-MYOCY437H mice topically 
treated with vehicle or 4Br-BnIm by fluorescent immunostaining and multiphoton 
microscopy. Trabecular meshwork (TM) and ciliary body (CB) are marked. (B) 
Quantification of (A) showing fluorescent intensity translating to myocilin accumulation 
levels comparing WT + vehicle (n=6) group to WT + 4Br-BnIm (n=4). There is no 
significant difference between wildtype mice treatment groups (p=.9588).  (C) 
Quantification of (A) showing myocilin accumulation in both Tg mouse treatment groups 
compared to WT mice. Tg-MYOCY437H + vehicle (n=14) have significantly more 
myocilin accumulation compared to WT mice (p=.0002). Tg-MYOCY437H + 4Br-BnIm 
(n=10) are not significantly different in myocilin accumulation compared to WT mice 
(p=.5933). Scale bar, 40uM. Statistical analysis carried out using two-tailed t-test. 
*P<.05, **P<.001, ***P<.0001. 
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Figure 3.4 Topical ocular 4Br-BnIm restores scotopic and photopic vision in Tg-
MYOCY437H mice. (A) Representative tracings of average scotopic (N35-P50) wave 
amplitudes in dark-adapted mice. (B) Quantification of (A) comparing WT treatment 
groups (WT + vehicle (n=4), WT + 4Br-BnIm (n=6)) N35-P50 wave amplitude. 
Statistically, there was no difference between WT groups (p=.8255), allowing us to 
group all WT mice together (n=10) (40.7 ± 2.7uV). (C) Quantification of (A) comparing 
Tg treatment groups (Tg + vehicle (n=7), Tg+4Br-BnIm (n=8)) to WT group. Tg mice 
treated with vehicle had significantly diminished (p=.0134) N35-P50 wave amplitude 
compared to WT mice (28.8 ± 3.0uV to 40.7 ± 2.7uV). Tg mice treated with Grp94 
inhibitor were not statistically different (p=.3652) from WT mice (36.5 ± 3.6uV to 40.7 ± 
2.7uV). This shows a recovery in N35-P50 wave amplitude in Tg mice following Grp94 
Inhibitor treatment. (D) Representative tracings of average photopic P50-N95 wave 
amplitudes in light-adapted mice. (E) Quantification of (D) comparing WT treatment 
groups (WT + vehicle (n=4), WT+4Br-BnIm (n=6)) P50-N95 wave amplitude. 
Statistically, there was no difference (p=.6850) between WT groups, allowing us to 
group all WT mice together (n=10) (45.0 ± 6.0uV). (F) Quantification of (D) comparing 
Tg treatment groups (Tg + vehicle (n=10), Tg+4Br-BnIm (n=8)) to WT group. Tg mice 
treated with vehicle had significantly diminished (p=.0140) P50-N95 wave amplitude 
compared to WT mice (27.4 ± 2.4uV to 45.0 ± 6.0uV). Tg mice treated with Grp94 
inhibitor were not statistically different (p=.5310) from WT mice (39.6 ± 5.6uV to 45.0 ± 
6.0uV). This shows a recovery in P50-N95 wave amplitude in Tg mice following Grp94 
Inhibitor treatment. Statistical analysis carried out using two-tailed t-test.  *P<.05. 
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Figure 3.5 Topical ocular 4Br-BnIm preserves RGC viability in Tg-MYOCY437H 
mice. (A) Representative images showing gamma-synuclein (Abcam (55424)) positive 
cells translating to viable retinal ganglion cells in whole mounted retinas. Positive cell 
threshold was determined using ImageJ analysis software. (B) Quantification of (A) 
comparing gamma-synuclein positive retinal ganglion cells in WT (n=3) to Tg mouse 
treatment groups. Tg + vehicle (n=4) treated mice had significantly less gamma-
synuclein positive cells than WT mice (p=.0002). Tg + 4Br-BnIm (n=4) mice did not have 
a significantly different amount of gamma-synuclein positive cells (p=.7945). (C) 
Representative images showing gamma-synuclein staining intensity of retinal ganglion 
cells in whole mounted retinas. (D) Quantification of (C) comparing gamma-synuclein 
staining intensity in WT (n=3) to Tg mouse treatment groups. Tg + vehicle (n=4) treated 
mice had significantly lower gamma-synuclein intensity than WT mice (p=.0023). Tg + 
4Br-BnIm (n=4) mice did not have a significantly different intensity of gamma-synuclein 
staining (p=.5846). Scale bar, 40uM. Statistical analysis carried out using two-tailed t-
test. *P<.05, **P<.001, ***P<.0001. 
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Figure 3.6 4Br-BnIm inhibits Grp94 association with mutant myocilin, reducing 
pathologies associated with POAG. In a healthy eye, myocilin is produced in the ER 
of TM cells.  If there is a mutation in the myocilin genome, a protein product is produced 
that readily accumulates and aggregates due to recognition by Grp94. If mutant myocilin 
is allowed to aggregate within the ER of TM cells, cellular dysfunction occurs, leading to 
POAG associated pathologies. Using the specific Grp94 inhibitor, 4Br-BnIm, Grp94 
association with mutant myocilin is inhibited allowing for alternative degradation via 
autophagy. Myocilin degradation restores TM cell function, leading to reduced IOP and 
retinal cell preservation. 
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Chapter Four1: 
Targeting the ER-Autophagy System in the Trabecular Meshwork to Treat 
Glaucoma 
4.1 Abstract 
A major drainage network involved in aqueous humor dynamics is the conventional 
outflow pathway, which is gated by the trabecular meshwork (TM). The TM acts as a 
molecular sieve, providing resistance to aqueous outflow, which is responsible for 
regulating intraocular pressure (IOP). If the TM is damaged, aqueous outflow is 
impaired, IOP increases and glaucoma can manifest. Mutations in the MYOC gene 
cause hereditary primary open-angle glaucoma (POAG) by promoting the abnormal 
amyloidosis of the myocilin protein in the endoplasmic reticulum (ER), leading to ER 
stress-induced TM cell death. Myocilin accumulation is observed in approximately 70-
80% of all glaucoma cases suggesting that environmental or other genetic factors may 
also promote myocilin toxicity. For example, simply preventing myocilin glycosylation is 
sufficient to promote its abnormal accretion. These myocilin amyloids are unique as 
there are no other known pathogenic proteins that accumulate within the ER of TM cells 
and cause toxicity. Moreover, this pathogenic accumulation only kills TM cells, despite 
expression of this protein in other cell types, suggesting that another modifier exclusive  
 
 
1This work was previously published (Stothert AR et al, 2015) and is used with the permission of 
the publisher 
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to the TM participates in the proteotoxicity of myocilin. ER autophagy (reticulophagy) is 
one of the pathways essential for myocilin clearance that can be impacted dramatically 
by aging and other environmental factors such as nutrition. This review will discuss the 
link between myocilin and autophagy, evaluating the role of this degradation pathway in 
glaucoma as well as its potential as a therapeutic target. 
 
4.2 Introduction 
Aqueous humor is a watery, ionic fluid, much like plasma in the blood, produced 
by the ciliary body that fills the anterior chamber of the eye [89]. Unlike the vitreous 
humor in the vitreous chamber of the eye, aqueous humor is constantly produced; 
therefore, in order to maintain a homeostatic environment, it must be constantly 
recycled out of the eye.  Regulatory aqueous outflow occurs by two pathways in the 
anterior chamber: the conventional pathway, comprised mainly of the TM, and the 
unconventional outflow pathway, comprised of drainage channels located at the angle 
between the ciliary muscle and the iris. The conventional pathway regulates upwards of 
85% of the aqueous outflow that occurs in the anterior chamber [90]. 
TM is the major component of the conventional outflow pathway, comprised of 
TM cells, juxtacanalicular connective tissue (JCT), the inner walls of Schlemm’s canal, 
Schlemm’s canal, the collector channel, and finally the episcleral vein, which carries 
aqueous humor back to systemic circulation [91, 92]. The TM is located at the 
iridocorneal junction of the anterior chamber, the area where the iris forms a junction 
with the cornea. In addition to giving the eye its shape, aqueous humor is responsible 
for providing nutrients to the avascular structures of the anterior chamber, including the 
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lens and cornea [89, 90]. However, one of the more important functions aqueous humor 
provides to the microenvironment of the eye is producing IOP [89], which is largely 
regulated by resistance of outflow provided by the TM in the conventional outflow 
pathway. Studies have shown that resistance to outflow is increased with age and in 
ocular disorders, such as glaucoma, where IOP elevation is a pathological hallmark 
[90]. 
Glaucoma is a neurodegenerative protein misfolding disorder, characterized by 
retinal ganglion cell (RGC) death and optic nerve (ON) axon damage leading to 
progressive irreversible vision loss [31, 52-55].  Glaucoma is the second leading cause 
of blindness worldwide, with over 60 million individuals suffering from the disease. In the 
United States alone, it is estimated that 2-3 million people have glaucoma, with over 
120,000 individuals suffering blindness due to the disease [31, 56, 77]. The most 
common forms of glaucoma include open-angle glaucoma, angle-closure glaucoma, 
normal-tension glaucoma, and congenital glaucoma. Although all forms of glaucoma are 
seen throughout the population, over 90% of cases involve a form of POAG [32, 33]. In 
POAG aqueous drainage channels remain exposed, but the TM network is damaged 
preventing proper outflow [33]. POAG arising from distinct mechanisms is often 
associated with accumulation of the glycoprotein myocilin, within the TM and Schlemm’s 
canal [22, 24, 34, 35, 41].  
 
4.3 Normal Intracellular Myocilin Processing 
Understanding the normal features of myocilin protein could help to elucidate 
why this protein accumulates in the glaucomatous eye. Myocilin is a ubiquitous 504 
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amino acid (aa) secreted glycoprotein expressed in both ocular and non-ocular tissues. 
In the eye, myocilin is found in the TM, sclera, ciliary body, choroid, cornea, iris, retina, 
and ON [93]. Outside the eye, myocilin is expressed in tissues of the peripheral nervous 
system [94]. Structurally, myocilin consists of an N-terminal region containing a signal 
peptide sequence (aa 1-32), a helix-turn-helix (aa 18-58) and a leucine zipper domain 
containing two coiled-coil domains (aa 74-110 and aa 118-186) responsible for 
coordinating protein-protein interactions [3, 77].  Myocilin is a glycoprotein that normally 
undergoes asparagine-linked glycosylation at aa residues 57–59 (Asn-Glu-Ser) [22, 95]. 
The C-terminal globular region contains the olfactomedin (OLF) domain (aa 230-504) 
[40, 77], an evolutionarily conserved region of amino acids first discovered in the 
olfactory neuroepithelium. In humans, the OLF domain is found within a group of 
glycosylated proteins important in the organization of the nervous system during 
development [34, 96]. Though myocilin is expressed throughout the body, its 
physiological function is yet unknown. Recent studies have suggested the importance of 
myocilin in oligodendrocyte differentiation and axonal myelination [97], and myocilin 
may play a role in retinal cell programmed death during development [98].  
 The secretory pathway is responsible for synthesis, folding, and delivery of a 
wide range of cellular proteins, including myocilin [84, 85]. This pathway is particularly 
important in correctly coordinating the localization of newly formed proteins to specific 
organelles and to the extracellular space [85]. The pathway is comprised of the rough 
endoplasmic reticulum (ER), ER-exit sites, ER-to-Golgi intermediate compartment 
(ERGIC), the Golgi complex, and post-Golgi carriers [84]. During ribosome synthesis of 
a polypeptide, proteins that are to be secreted are targeted by a signal recognition 
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particle (SRP), a molecule that targets hydrophobic peptide signal sequences on the N-
terminal domain of a protein. SRPs direct the translocation of newly forming 
polypeptides into the ER membrane via translocons, or channels in the ER membrane, 
for continued translation and post-translational modifications required for secretion. 
Once in the ER membrane, post-translational modifications such as signal peptide 
cleavage, glycosylation, disulfide bond formation, and glycosidase trimming occur to 
ensure proper protein folding.  
 The cleavage of the N-terminal signal peptide sequence is a common 
modification for many proteins that enter the ER, including myocilin. Cleavage of this 
sequence occurs via signal peptidase complex (SPC), a 4-subunit polypeptide. Most of 
the SPC subunits are required for cell viability, except the Sec11 subunit, which 
contains the protease active site [84]. The SPC cleaves off the N-terminal signal peptide 
sequence, exposing glycosylation sites on the protein [84, 85]. Asparagine –linked (N-
linked glycosylation) is a post-translational modification where oligosaccharides are 
attached to asparagine residues in the N-terminal domain of the protein [99].  
Oligosaccharyltransferase enzyme (OST), an 8-subunit polypeptide, carries out the 
addition of oligosaccharides. Cells require the majority of the OST subunits for viability, 
though the Stt3 domain is dispensable and only required for catalytic activity. N-linked 
glycosylation of a protein is thought to be important in thermodynamic stability, 
solubility, and protein folding [99]. Glycosylated proteins in the ER membrane then form 
disulfide bonds at free sulfhydryl groups on cysteine residue side chains due to the 
oxidizing environment within the ER lumen. A specialized family of disulfide isomerases 
is required for the formation, reduction and isomerization of these disulfide bonds, 
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ensuring correct protein folding [100].  Once the signal sequence is cleaved, proteins 
are glycosylated and disulfide bonds form. Following this process, the final step required 
for proper protein folding is the trimming of glucose residues from the protein 
oligosaccharide core. Glucosidases (Gls1/Gls2) are enzymes that rapidly trim glucose 
residues, allowing for proper chaperone folding [101]. Mns1 and Htm1, enzymes that 
cleave mannose residues, generate signals for protein degradation by recognizing 
proteins that are terminally misfolded [102].  
 After post-translational modifications, proteins are exported to ER-exit sites, 
areas that have a high concentration of coat-protein complex II (COPII) [85, 103]. COPII 
is a molecule that forms a coat around properly folded proteins, promoting vesicle 
formation for Golgi transport. COPII vesicle formation is activated by the ER GTPase 
Sar1, which interacts with Sec proteins responsible for protein recruitment to form 
Sec23-24 and Sec13-31 complexes. The Sec23-24 complex is vital for protein capture 
and the Sec13-31complex is necessary for COPII coat formation [103, 104]. Once 
COPII vesicles are formed around proteins, they can fuse with each other forming pre-
Golgi intermediates [105], or fuse with already made ERGIC [106] and directed to the 
Golgi complex (Fig. 4.1A), where they are further modified and processed, allowing 
delivery to their final destination [107, 108]. Each step along this pathway represents a 
potential point where myocilin processing could go awry. This entire process is 
particularly relevant for understanding how a group of POAG cases that are caused by 
mutations in the secreted myocilin protein. 
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4.4 Myocilin Misfolding Propagates Glaucomatous Pathology 
Mutations in the MYOC gene are observed in ~30% of juvenile onset glaucoma 
cases, and 2-4% of patients with POAG. To date, over 70 glaucoma-causing myocilin 
mutations have been identified, with >90% found in the C-terminal OLF domain [3].  
Less than 10% of disease-causing mutations are located in the N-terminal domain. 
Mutations in the C-terminus of the myocilin protein result in conformational changes in 
the tertiary structure of the protein, namely that charged residues important for 
regulating cleavage and secretion are no longer solvent-exposed [2, 33, 37, 56] (Table 
4.1). These mutations thus induce a toxic gain of function for the cell via myocilin protein 
misfolding and abnormal amyloidosis in the ER of TM cells [43]. Based on the genetic 
evidence, it is thought that the point mutations in the MYOC gene make the protein 
prone to misfolding, intracellular retention and subsequent aggregation somewhere 
along the secretory pathway in TM cells. This leads to ER stress, causing TM cell death, 
dysfunctional aqueous humor outflow, increased IOP and eventually optic nerve 
damage [22, 35, 37].  
In addition to inherited mutations in myocilin, inhibition of post-translational 
modifications in WT myocilin can alter secretion leading to intracellular accumulation. 
Our laboratory examined this phenomenon by utilizing two pharmacological inhibitors, 
tunicamycin and brefeldin a. Tunicamycin is a well-documented inhibitor of N-linked 
glycosylation, leading to improper protein folding; Brefeldin A is an inhibitor of ER-Golgi 
transport. Treatment of cells overexpressing WT myocilin with Tunicamycin or Brefeldin 
A resulted in increased levels of intracellular myocilin [43]. Moreover, prolonged 
treatment with glucocorticoids can result in increased myocilin deposition within the ER 
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of TM cells, which has been documented to cause glaucoma pathology in humans [109-
111]. We have shown that WT myocilin, similar to other secreted proteins, is typically 
degraded through the proteasomal-dependent ER-associated degradation (ERAD) 
mechanism (Fig. 4.1b) [43, 84, 85]. ERAD is a process that uses the VCP/p97 complex 
to typically triage misfolded proteins from the ER lumen to the cytosol for ubiquitination 
and subsequent proteasomal degradation [112].  But in cases where misfolded myocilin 
is produced, either by mutation or altered post-translational modification, this clearance 
mechanism fails, leading to myocilin aggregation, ER stress and TM cell toxicity. 
Therefore, if ERAD could be restored for these misfolded myocilin species, or another 
clearance mechanism could be engaged, such as autophagy, myocilin toxicity in the TM 
could be reduced. 
 
4.5 Autophagic Degradation of Misfolded Proteins Promotes Cellular 
Homeostasis 
Even in normally functioning cells, if there is a proteotoxic stress leading to 
accumulation of misfolded proteins in the ER, the unfolded protein response (UPR) is 
activated. If the activation is acute, then the UPR is beneficial to the cell, but if the 
activation is chronic, it can facilitate cell death [86, 113, 114]. In cases of glaucoma 
caused by mutations in the MYOC gene, the UPR seems to be chronically activated, 
suggesting that this could be a primary mechanism of TM cell death. While trying to 
stimulate ERAD of mutant myocilin is one approach for overcoming chronic UPR 
activation, one caveat of this mechanism is that ubiquitin-proteasome degradation is 
limited to monomeric proteins. For an amyloidogenic protein like myocilin, this simply 
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may never work. When the cell needs to degrade damaged organelles or aggregated 
proteins, a less specific but more robust ER autophagic mechanism of clearance 
(reticulophagy) is available. Engaging this system may be much more efficient for 
facilitating removal of myocilin aggregates from the ER [115].  
 Autophagy is a general term used for the process involving degradation by 
lysosome-containing vesicles. There are at least three types of autophagy, differing by 
their means of delivering material to the lysosome for degradation: macroautophagy, 
microautophagy, and chaperone-mediated autophagy [116, 117]. During chaperone-
mediated autophagy, substrates are recognized by a particular amino acid peptide 
sequence and are translocated into the lumen of a lysosome for degradation [28].  
Microautophagy is a less specific process where the lysosomal membrane invaginates 
or sequesters material in the cytosol for degradation within the lysosome [118].  In 
addition, organelles such as the mitochondria and the ER can degrade their protein 
content via distinct routes that ultimately utilize macroautophagy [119]. 
 Macroautophagy is a catabolic process necessary for cell homeostasis [53, 117, 
120]. It is upregulated when cells require intracellular nutrients and energy such as 
during starvation, growth factor withdrawal, or in the context of high-energy demand 
[95]. Additionally, macroautophagy can be upregulated in times of cellular proteotoxic 
stress, when misfolded proteins accumulate. Macroautophagy is a multi-step process 
consisting of four stages: initiation, nucleation, maturation, and degradation. Initiation 
occurs by the down-regulation of the mammalian target of rapamycin (mTOR) pathway 
[116]. In times of starvation autophagy-related protein 13 (Atg13) and unc51-like 
autophagy activating kinase (Ulk1/2) are upregulated leading to the inhibition of the 
74 
 
mTOR pathway. Conversely, when growth factors, such as insulin-like growth factor, 
bind to growth factor receptors, initiation of receptor tyrosine kinase signaling and 
subsequent activation of protein kinase B (AKT) occurs. AKT activation inhibits the 
major inhibitory proteins of the mTOR pathway, tuberous sclerosis 1 and 2 (TSC1/2), 
resulting in the activation of the mTOR pathway and subsequent inhibition of 
macroautophagy [121]. Additionally, mTOR inhibition leads to ULK1 phosphorylation 
and activation of autophagic effectors Beclin1 and phosphatidylinositol 3-kinase (Vps34) 
[95].  
Following initiation, nucleation is the process in which the autophagosome, the 
unique organelle associated with macroautophagy, forms. Phosphorylated 
Beclin1/Vps34, along with p150, form a stable complex that initiates formation of the, 
pre-autophagosome, or phagophore [121]. The phagophore matures into the 
autophagosome and fully surrounds the target cytosolic components. This process 
involves the elongation of the phagophore membrane via the incorporation of 
microtubule-associated protein 1A/1B-light chain 3 (LC3) into the membrane. LC3 
mediates autophagosome growth and cytoplasmic cargo recruitment, and provides a 
scaffold to transport fully formed autophagosomes to the lysosomes. Once the 
autophagosome has fully formed around cytoplasmic constituents, LC3 mediates 
dynein-dependent microtubule trafficking to lysosomes. Finally, the autophagosome 
fuses with the lysosome via the SNARE proteins VAMP8, Vti1B, and Lamp2, and 
results in the formation of the autolysosome.  Following autolysosome formation, the 
autophagic cargo is degraded and then recycled back to the cytosol for cell re-uptake 
[95, 121].   
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Until recently macroautophagy was thought of as a non-selective degradation 
pathway, but current research has proposed the idea of organelle-specific autophagy, 
including ribophagy (ribosomes), mitophagy (mitochondria) and reticulophagy (ER). 
While specific details on individual organelle autophagy remain largely uncharacterized, 
it is postulated that cellular constituents are targeted for these distinct autophagic 
pathways by Atg upregulation leading to autophagosome formation or possibly by 
accumulation of intra-ER ubiquitinated proteins [119]. The latter is supported by work 
from our laboratory showing that only mutant/misfolded myocilin becomes ubiquitinated 
within the ER following treatment with epoxomicin, a proteasome inhibitor [43]. In this 
way, the accumulation of misfolded, ubiquitinated myocilin could activate reticulophagic 
degradation.  
 
4.6 TM Autophagic Dysregulation Promotes Ocular Disorders 
Studies have shown that increasing macroautophagy can delay the aging 
process, and extend tissue longevity. This was first observed in the C.elegans model, 
where inhibition of the insulin-like growth factor receptor induced autophagy [122].  
Conversely, mutation of Atg genes resulted in decreased tissue longevity [122]. 
Moreover, age-related reductions in Beclin1 [123], Sirtuin1 (A modulator of mTOR 
inhibition)[124], and Atg5/7 [125] protein levels have been observed in aged tissue. 
Additionally, decreased levels of ULK1 and LC3 have been observed in aged tissue. As 
glaucoma is a slowly progressing ocular disorder and pathology increases are 
associated with aging, it is possible this could largely be an effect of reduced autophagic 
protein clearance in TM cells.  
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Studies in primary human TM (hTM) cells have also shown that during glaucoma, 
the autophagic mechanism in TM cells is dysregulated. Recent research has indicated a 
dysregulation of the autophagic pathway and reduction of the autophagic response to 
oxidative stress in TM cells isolated from patients with glaucoma [53]. Interestingly, this 
research determined an overall reduction of LC3 in TM cells of glaucoma patients 
compared to controls [53]. Additionally, there was an increase in senescence-
associated-β-galactosidase (SA-β-Gal) activity, which is shown to be upregulated when 
autophagy is inhibited in primary human fibroblasts [126]. Moreover, they observed an 
increase in lipofuscin, or non-degradable lysosomal content, in TM cells of glaucoma 
patients compared to control cells [53]. Other proteins associated with autophagy found 
to be down regulated during glaucoma were sequestosome-1 (p62), a scaffold that 
targets ubiquitinated proteins for autophagic degradation, scCTSB, a lysosomal protein, 
and LC3B-II [53]. Taken together, these data show that autophagic clearance 
mechanisms are dysfunctional in TM tissue of glaucoma patients. Thus, restoring these 
pathways could be beneficial in disease. 
 
4.7 Grp94 Prevents Misfolded Myocilin Degradation via Autophagy 
ER homeostasis, including ERAD and reticulophagy pathways, is mediated by 
chaperone activity. Chaperones aid in the proper folding of proteins under physiological 
conditions as well as in times of ER stress [28, 127, 128]. Stress caused by 
accumulation of terminally misfolded proteins activates the UPR, resulting in cessation 
of protein translation [113, 127] and increased production of molecular chaperones 
[114]. We recently performed a small-interfering RNA (siRNA) screen on several ER-
77 
 
associated chaperones to examine their effects on overexpressed I477N mutant 
myocilin or WT myocilin in Hek293T cells [43]. Interestingly, only knockdown of glucose-
regulated protein 94 (Grp94), the ER-specific isoform of Hsp90, caused intracellular 
I477N mutant myocilin reduction. Under physiological conditions, Grp94 is inactive 
[129]. During ER stress, Grp94 is associated with ER quality control and aids in the 
proper folding of misfolded proteins.  Grp94 also associates with the ERAD-associated 
osteosarcoma amplified 9 (OS-9) protein and acts to shuttle terminally misfolded 
monomeric protein to the ER membrane for subsequent proteasomal degradation [129, 
130] 
 This intracellular reduction was also observed in cells overexpressing four other 
common glaucoma-associated myocilin mutations [54]. Interestingly, Grp94 knockdown 
had no effect on intracellular or secreted levels of WT myocilin.  Moreover, following 
myocilin immunoprecipitation (IP), we found that Grp94 associated with mutant protein 
but not WT myocilin [43], highlighting the specificity offered by this chaperone. Using a 
cycloheximide (a potent inhibitor of protein translation) chase experiment, we were able 
to determine that the half-life of intracellular mutant myocilin was decreased after Grp94 
inhibition. Additionally, we observed an increase in high-molecular weight myocilin 
species with Grp94 overexpression, and conversely, reduction in high-molecular weight 
myocilin species after Grp94 knockdown [43]. This led us to believe that Grp94 was 
preserving mutant myocilin, and possibly driving protein aggregation.   
Importantly, Grp94 inhibition also reduced intracellular mutant myocilin levels, as 
well as cellular toxicity associated with mutant myocilin overexpression, in primary hTMs 
[54]. Interestingly, Grp94 inhibition had no effect on normally folded WT myocilin levels. 
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However, when N-linked glycosylation of WT myocilin was blocked by tunicamycin, we 
observed an increased association with WT myocilin and Grp94. This was accompanied 
by sensitization to Grp94 inhibition [43]. Moreover, Grp94 could stimulate aggregation of 
WT myocilin OLFs in vitro, a process that could be mitigated by the addition of Grp94 
inhibitor [54]. These data led us to the conclusion that Grp94 recognizes misfolded 
myocilin species within the ER, but iteratively attempts to triage the protein through 
ERAD unsuccessfully. This leads to myocilin protein aggregation in the ER and 
subsequent TM cell toxicity (Fig. 4.2).  
To explore the feasibility of Grp94 inhibition as a potential therapeutic 
mechanism, one first must examine the importance of Grp94 in an organism. Grp94, as 
a molecular chaperone of the ER, has relatively few client proteins [44]. Interestingly, 
despite this Grp94 is necessary for embryonic development. This has been shown in 
studies looking at both heterozygous (+/-) and homozygous (-/-) knockdown of Grp94 in 
murine models and of gp93 in drosophila [131]. While the  -/- mice have lethality and a 
number of other functional deficits,  +/- mice survive and seem healthy, suggesting that 
partial but not complete depletion of Grp94 may be a viable therapeutic strategy [132]. 
Moreover, recent studies have shown that targeted knockout in discreet tissues does 
not impact viability [86]. However, Grp94 does play important roles in immune cell and 
liver function [133, 134], and others, suggesting that caution will be necessary moving 
forward with therapeutic approaches targeting this protein.  
 While previous data suggests that the inhibition of Grp94 association with 
misfolded or mutant myocilin leads to intracellular degradation of the myocilin protein 
and therefore could be a potential therapeutic target to treat glaucoma, the mechanism 
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by which degradation of this protein occurs was still not known. To determine if the 
autophagic pathway was involved in misfolded myocilin protein clearance, cells 
overexpressing mutant myocilin (I477N) were co-transfected with Grp94 siRNA and 
either Lamp2 or Beclin1 siRNA, two well-characterized components of the autophagy 
pathway. Indeed the addition of Lamp2 or Beclin1 siRNA abrogated intracellular 
myocilin clearance following Grp94 knockdown [43]. Thus, inhibiting Grp94 shunts 
misfolded myocilin towards the autophagic degradation pathway, a pathway that must 
be functional for mutant myocilin turnover (Fig. 4.3). In fact, since TM cell dysfunction 
prevents normal aqueous humor outflow, nutrient delivery to these cells is impaired, 
which would normally trigger macroautophagy and possibly facilitate misfolded myocilin 
clearance, restoring balance to the outflow pathway. But, because of the interaction of 
Grp94 with myocilin, its autophagic degradation is prevented, allowing glaucomatous 
pathology to perpetuate. Therefore, discovering therapeutic measures to enhance the 
ER autophagic mechanism, allowing for misfolded myocilin to be degraded, could lead 
to restoration of TM cell function and reduction in glaucomatous pathology. In fact, 
perhaps combining Grp94 inhibition with enhancers of reticulophagy could work 
together synergistically to promote myocilin clearance and rescue glaucoma caused by 
myocilin toxicity. 
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Table 4.1 List of known mutations in the MYOC gene that lead to glaucoma. Bold 
denotes mutations in the N-terminus; Underline denotes mutations in the C-terminus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Mutation (AA) Gene Location Ref 
C25R Exon1 [33] 
R46X   Exon1 [2] 
R82C Exon1 [4] [2] 
R91X Exon1 [135] 
R126W Exon1 [136] 
C245Y Exon 3 [7] 
G246R    Exon 3 [56] 
V251A    Exon 3 [137] 
G252R    Exon 3 [56] 
R272G Exon 3 [56] 
P274R Exon 3 [138] 
W286R   Exon 3 [2] 
T293K Exon 3 [2] 
E300K Exon 3 [135] 
S313F Exon 3 [139] 
E323K Exon 3 [56] 
Q337R Exon 3 [56] 
R342K Exon 3 [140] 
I345M Exon 3 [137] 
Y347X Exon 3 [2] 
I360N Exon 3 [141] 
P361S Exon 3 [2] 
A363T Exon 3 [141] 
G364V Exon 3 [2] 
G367R Exon 3 [142] 
Q368X Exon 3 [2] 
P370L Exon 3 [56] 
T377M Exon 3 [2] [142] 
D380G Exon 3 [13] 
D380H Exon 3 [13] 
D380N Exon 3 [13] 
D380A Exon 3 [56] 
S393N Exon 3 [137] 
S393R Exon 3 [2] 
K423E Exon 3 [56] 
V426F Exon 3 [56] 
A427T Exon 3 [8] 
C433R Exon 3 [143] 
Y437H Exon 3 [2] 
A445V Exon 3 [2] 
T448P Exon 3 [56] 
N450D Exon 3 [137] 
Y453del Exon 3 [2] 
I465M Exon 3 [2] 
R470C Exon 3 [2] 
Y471C Exon 3 [135] 
I477N Exon 3 [2] 
I477S Exon 3 [56] 
N480K Exon 3 [56] 
P481S Exon 3 [2] 
P481T Exon 3 [2] 
P481R Exon 3 [2] 
E483X Exon 3 [2] 
I499F Exon 3 [56] 
S502P Exon 3 [56] 
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Figure 4.1 Normal intracellular processing of myocilin. After signal recognition 
particle (SRP) targeting and translocation of a newly forming myocilin polypeptide to the 
endoplasmic reticulum lumen, posttranslational modifications occur to ensure proper 
folding of the protein. If these modifications are successful (A), the newly formed, 
properly folded, protein will be sent to the Golgi apparatus via COPII coat formation for 
packaging and delivery to specific cellular organelles or the extracellular space.  
However, if these modifications do not properly occur (B), and the protein becomes 
terminally misfolded, the intra-ER degradation mechanism, known as ERAD, will 
degrade the protein through a proteaosomal dependent manner for peptide recycling. 
This method requires the ubiquitination of misfolded proteins, and is only substantial if 
the misfolded protein is monomeric. 
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Figure 4.2 Grp94 association with mutant myocilin promotes intracellular 
accumulation. Mutations in the MYOC gene lead to the production of myocilin protein 
that readily misfolds and is prone to aggregation. Grp94 is an ER-associated co-
chaperone that recognizes pre-aggregated misfolded myocilin, preventing ERAD 
proteasomal degradation, leading to aggregation within the ER. Proteotoxicity caused 
by aggregated myocilin in the ER leads to TM cell death and aqueous outflow 
dysfunction, promoting the pathologies associated with glaucoma.   
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Figure 4.3 Inhibition of Grp94 interaction with mutant myocilin promotes 
autophagic degradation. Through siRNA knockdown or pharmacological inhibition, 
Grp94 association with misfolded myocilin can be prevented, inhibiting protein 
aggregation. After inhibition, misfolded myocilin can be processed into transport 
vesicles for transport out of the ER lumen to the cell cytosol, where these vesicles fuse 
with lysosomes promoting autophagic degradation of the misfolded protein. As 
aggregated misfolded myocilin is cleared form the ER of TM cells, aqueous outflow 
becomes restored. 
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Chapter Five: 
Final Considerations 
This study has demonstrated that intra-ER misfolded myocilin mechanics can be 
altered by the chaperone, Grp94. Specifically, Grp94 recognition of terminally misfolded 
myocilin prevents ERAD clearance promoting protein accumulation precipitating cellular 
toxicity. Through pharmacological inhibition, misfolded myocilin clearance and 
degradation can occur, albeit through the robust autophagic pathway. The major 
findings of this study demonstrate how the alteration of Grp94 interaction with mutant 
myocilin can lead to 1) reduced intracellular myocilin accumulation, 2) reduced TM 
cellular toxicity, 3) promotion of the autophagic clearance mechanism, and 4) 
pathological rescue of glaucoma phenotypes. We have clearly shown that Grp94 
association with misfolded myocilin in the ER of TM cells is a major contributor to 
myocilin accumulation causing glaucomatous pathologies. This study supports the 
possibility of developing novel therapeutics inhibiting Grp94’s association with misfolded 
myocilin as a viable treatment option for POAG.  
For quite some time, chaperone modulation has been a therapeutic target for 
multiple diseases including, Alzheimer’s disease [66, 144], Parkinson’s disease [145, 
146], and Cancer [78, 147]. Specifically, Grp94 inhibition has been previously studied as 
a potential target for cancer treatment [44, 148]. However, until our work outlined in this 
manuscript, Grp94 was not considered a target for potential glaucoma treatment. In fact, 
until our work, Grp94 was not known to be associated with myocilin in cases of myocilin-
associated glaucoma. With our previously discussed work, we have clearly shown the 
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importance of Grp94 associating in progressing myocilin-associated glaucoma 
pathology, as well as discovered a novel target for therapeutic intervention. Moreover, 
we have shown that topical administration of a Grp94 inhibitor can alleviate pathologies 
associated with myocilin-induced glaucoma. Development of new Grp94 inhibitors that 
are more potent at lower concentrations, as well as have greater anterior chamber 
bioavailability when applied topically, would be vital in progressing this research forward 
into higher organisms, including humans. These studies support the idea of specific 
therapeutic intervention targeting the underlying glaucoma disease mechanism as a 
viable means for not only reducing symptoms, but curing the disease all together.  
Clear limitations arise in our approach as currently the underlying disease 
mechanism of glaucoma is still unknown. While our research has shown a direct link to 
Grp94 association with misfolded myocilin as a mediating factor of myocilin 
accumulation and toxicity, the specific disease mechanism must be discovered to fully 
understand potential therapeutic targets. Additionally, while topical administration of 
ophthalmic drugs continue to be the gold standard in treating various ailments of the 
eye, more direct drug delivery may be necessary to reduce unwanted off target effects. 
Previous clinical trials studying the effects of Hsp90 modulation in the treatment of 
cancer and other diseases have shown promise, however, off-site toxicities have 
prevented research from advancing [44]. Additionally, while a majority of glaucoma 
research centers on myocilin accumulation in the ER of TM cells, the biological 
relevance of myocilin in the human body still remains unknown. While groups have 
postulated myocilin’s importance in cell proliferation, peripheral axon myelination, 
oligodendrocyte differentiation, and optic nerve myelination, its specific function remains 
86 
 
relatively unknown [94, 97, 149]. Therefore, specifically targeting accumulated myocilin 
in the ER of TM cells would be necessary to prevent off-target toxicities from systemic 
or broad administration.  
Finally, while we have shown promising results in targeting Grp94 as a means for 
reducing POAG pathology, other forms of glaucoma, including closed-angle and steroid 
induced glaucoma, remain without a viable curative treatment option. Next steps in our 
research will center on determining to what extent, if any, myocilin accumulation plays in 
the development of other subtypes of glaucoma. Determining if myocilin is directly 
responsible for multiple glaucoma subtypes would allow us to progress our research, 
determining if Grp94 inhibition is a viable treatment method for all glaucomas. 
Additionally, determining the specific mechanism of misfolded myocilin degradation 
following Grp94 inhibition would be imperative in advancing this work into clinical trials. 
While we have shown evidence linking autophagic degradation to misfolded myocilin 
clearance, the specific mechanism, and proteins involved are still unknown. Determining 
the specific mechanism of degradation could also lead to new targets for potential 
therapeutics. While this research is still in its infancy, promising results could lead to the 
first curative therapeutic for treating POAG.  
Overall our findings suggest there is a direct relationship between Grp94 and 
misfolded myocilin, which leads to pathologies associated with POAG. Through specific 
pharmacological inhibition, we were able to alleviate myocilin-associated glaucoma 
pathology, while promoting misfolded myocilin clearance. This work validates Grp94 as 
a potential therapeutic target for treatment of myocilin-associated POAG. 
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